WO2025036281A1 - Molécules d'arnt suppresseurs modifiées et procédés - Google Patents

Molécules d'arnt suppresseurs modifiées et procédés Download PDF

Info

Publication number
WO2025036281A1
WO2025036281A1 PCT/CN2024/110998 CN2024110998W WO2025036281A1 WO 2025036281 A1 WO2025036281 A1 WO 2025036281A1 CN 2024110998 W CN2024110998 W CN 2024110998W WO 2025036281 A1 WO2025036281 A1 WO 2025036281A1
Authority
WO
WIPO (PCT)
Prior art keywords
trna
seq
engineered
nucleotide
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2024/110998
Other languages
English (en)
Inventor
Jianguo ZHU
Lingjie Kong
Rong Huang
Yu Ding
Jianfeng DONG
Kangyun DONG
Anrui LU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Codone Biotechnology Co
Original Assignee
Shanghai Codone Biotechnology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Codone Biotechnology Co filed Critical Shanghai Codone Biotechnology Co
Priority to CN202480052068.6A priority Critical patent/CN121693567A/zh
Publication of WO2025036281A1 publication Critical patent/WO2025036281A1/fr
Priority to PCT/CN2025/091495 priority patent/WO2026001270A1/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Definitions

  • the present disclosure relates in some aspects to engineered transfer RNA (tRNA) molecules that restore translation of a coding nucleic acid containing a premature UGA/TGA stop codon by inserting an arginine (Arg) amino acid into the polypeptide in decoding the UGA/TGA codon.
  • tRNA transfer RNA
  • the present disclosure further relates to expression cassettes and vectors comprising nucleic acids encoding an engineered tRNA, pharmaceutical compositions comprising the expression cassettes, vectors, and/or the engineered tRNA, and methods of restoring translation and/or disease treatment involving engineered tRNA molecules.
  • Rare diseases also known as orphan diseases, are defined strictly according to their prevalence. In the United States, a disease is considered to be “rare” when it affects less than one person out of 1500; in Europe, less than one person out of 2000. To date, 6172 unique rare diseases have been described. 71.9%of these originated from genetic mutations, with the remainder being induced by viral or bacterial infections, allergies, or environmental effects (Nguengang Wakap, S., et al. (2020) Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. Feb; 28 (2) : 165-173. doi: 10.1038/s41431-019-0508-0. Epub 2019 Sep 16.
  • PMID: 31527858; PMCID: PMC6974615) About 263-446 million people are estimated to suffer from rare diseases globally at any point in time (Nguengang Wakap, S., et al. (2020) Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. Feb; 28 (2) : 165-173. doi: 10.1038/s41431-019-0508-0. Epub 2019 Sep 16. PMID: 31527858; PMCID: PMC6974615) . Unfortunately, 75%of rare disease patients are children, 30%of whom have life expectancies of less than 5 years (Benhabiles, H., et al. (2016) .
  • Nonsense mutations are well-studied point mutations that result in a premature termination codon (PTC) in the messenger RNA (mRNA) , which leads to decreased mRNA stability and truncated protein products (Khajavi, M., et al.
  • nonsense mutations are present in the mRNAs of various genes, and occur at different frequencies depending on the stop codon, including 41.8% (19, 101) TAG, 36.5% (16, 680) TGA, and 21.7% (9, 908) TAA PTCs.
  • the codon decoding Arginine (Arg) to TGA nonsense mutation counts for the most frequent transitions (9302) (data from the Human Gene Mutation Database https: //www. hgmd. cf. ac. uk/ac/index. php, accessed July 4, 2023) .
  • the NMD pathway relies on the ribosome for scanning of stop codons, as well as the presence of exon-junction complexes (EJCs) , which are deposited approximately 20-24 nt upstream of exon-exon junctions.
  • EJCs exon-junction complexes
  • the SURF complex consists of a protein kinase (SMG1) , an RNA helicase (UPF1) , as well as the peptide release factors eRF1 and eRF3.
  • the dominant strategy in the field has been to apply small molecules to promote PTC readthrough based on their role in inhibiting ribosome proofreading (e.g., aminoglycosides, Ataluren) , the NMD pathway (e.g., amlexanox) , and inducing mRNA-tRNA mispairing (e.g., pseudouridylation) (Spelier, S., et al. (2023) Readthrough compounds for nonsense mutations: bridging the translational gap. Trends Mol Med. Apr; 29 (4) : 297-314. doi: 10.1016/j. molmed. 2023.01.004. Epub 2023 Feb 22. PMID: 36828712) .
  • ribosome proofreading e.g., aminoglycosides, Ataluren
  • the NMD pathway e.g., amlexanox
  • mRNA-tRNA mispairing e.g., pseudouridylation
  • Another approach is to implement a gene therapy strategy to ensure the production of the correct protein, for instance, CRISPR-based gene editing of a faulty gene or delivery of transgene (Porter, J.J., et al. (2021) Therapeutic promise of engineered nonsense suppressor tRNAs. Wiley Interdiscip Rev RNA. Jul; 12 (4) : e1641. doi: 10.1002/wrna. 1641. Epub 2021 Feb 10. PMID: 33567469; PMCID: PMC8244042) .
  • the application of this approach is limited by the single target specificity and the risk of off-target effects.
  • suppressor tRNAs Following the development of in vivo delivery systems and genome-wide, transcriptome-wide, and proteome-wide analysis technologies, suppressor tRNAs have drawn attention for their potential to treat diseases caused by PTCs (Wang, J., et al. (2022) AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice. Nature. Apr; 604 (7905) : 343-348. doi: 10.1038/s41586-022-04533-3. Epub 2022 Mar 23. PMID: 35322228; PMCID: PMC9446716) .
  • Suppressor tRNAs are derived from naturally occurring tRNAs, with alterations of the anticodon to target a PTC (e.g., UAA, UAG, UGA) , and they carry a desired amino acid to restore full-length protein products for mRNAs containing PTCs.
  • a PTC e.g., UAA, UAG, UGA
  • suppressor tRNAs provide the potential to target various PTC induced genetic diseases with a single component and minor side effects (Wang, J., et al. (2022)
  • AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice. Nature. Apr; 604 (7905) : 343-348. doi: 10.1038/s41586-022-04533-3. Epub 2022 Mar 23. PMID: 35322228; PMCID: PMC9446716) .
  • tRNA engineered transfer RNA
  • the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon
  • the engineered tRNA comprises one or more modifications relative to a tRNA having the sequence of SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16; and wherein the one or more modifications comprise: i) an A to G substitution at the 1 st nucleotide 3’ to the anticodon; ii) a U to C substitution at the 4 th nucleotide 3’ to the anticodon; and/or iii) a CCA sequence attached to the acceptor arm at the 3’ end.
  • the engineered tRNA has a nucleotide sequence that is at least about 85%identical to SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16. In some embodiments of this aspect that may be combined with any of the preceding embodiments, the engineered tRNA contains no more than about 5 nucleotide substitutions relative to SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16. In some embodiments of this aspect that may be combined with any of the preceding embodiments, the engineered tRNA comprises an A to G substitution at the 1 st nucleotide 3’ to the anticodon.
  • the engineered tRNA comprises a U to C substitution at the 4 th nucleotide 3’ to the anticodon. In some embodiments of this aspect that may be combined with any of the preceding embodiments, the engineered tRNA comprises a CCA sequence attached to the acceptor arm at the 3’ end. In some embodiments of this aspect that may be combined with any of the preceding embodiments, the engineered tRNA has nucleic acid sequence selected from the group consisting of SEQ ID NOs: 2-8 and 61-64.
  • the engineered tRNA exhibits an increased stability in vivo as compared to a tRNA having the sequence of SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16.
  • the PTC readthrough capability is determined by a NanoLuc luciferase assay, RT-qPCR, Western Blot, Immunoprecipitation, Mass Spectrometry, and/or Immunofluorescence.
  • Another aspect of the present application provides a nucleic acid encoding the engineered tRNA of any one of the preceding embodiments.
  • Another aspect of the present application provides a vector comprising the nucleic acid of the preceding aspect.
  • the vector is a viral vector or a plasmid.
  • the vector is a viral vector, and wherein the viral vector is an adenoviral vector, an adeno-associated viral (AAV) vector, or a lentiviral vector.
  • the vector is an AAV 2/2 vector, an AAV 2/5 vector, an AAV 2/6 vector, an AAV 2/7 vector, an AAV2/8 vector, or an AAV 2/9 vector.
  • Another aspect of the present application provides a pharmaceutical composition
  • a pharmaceutical composition comprising the engineered tRNA of any one of the preceding embodiments, the nucleic acid of any one of the preceding embodiments, or the vector of any one of the preceding embodiments, further comprising a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier is a liposome or a lipid nanoparticle.
  • Another aspect of the present application provides a method of restoring translation of a coding nucleic acid of interest containing a premature UGA/TGA stop codon in a cell, comprising introducing to the cell the engineered tRNA of any one of the preceding embodiments, the nucleic acid of any one of the preceding embodiments, or the vector of any one of the preceding embodiments, wherein the engineered tRNA introduced into the cell or produced from the nucleic acid or vector recognizes and reads through the premature UGA/TGA stop codon, thereby restoring translation of the coding nucleic acid of interest containing the premature UGA/TGA stop codon.
  • the engineered tRNA restores at least 5%of the translation of the coding nucleic acid of interest containing a premature UGA/TGA stop codon relative to a corresponding coding nucleic acid not containing the premature UGA/TGA stop codon.
  • Another aspect of the present application provides a method of treating a disease associated with a premature UGA/TGA stop codon in an individual, comprising: administering to the individual an effective amount of the pharmaceutical composition of any one of the preceding embodiments.
  • the premature-stop-codon-associated disease is cystic fibrosis, muscular dystrophy, Alport syndrome, Stargardt disease, dilated cardiomyopathy, ⁇ -thalassemia or Liddle's syndrome.
  • the individual is human.
  • Another aspect of the present application provides an engineered tRNA of any one of the preceding embodiments, wherein the engineered tRNA exhibits increased PTC readthrough efficiency in vivo as compared to a tRNA having the sequence of SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16.
  • FIGS. 1A-1C show NanoLuc luciferase assays used to screen engineered tRNAs for PTC suppression efficiency.
  • FIG. 1A shows a schematic of two versions of a luciferase construct for a nonsense mutation suppression screen involving rescuing full-length luciferase and its activity.
  • the top and bottom panels depict different versions of the construct.
  • NanoLuc depicts a modified Luciferase protein coding genes (Promega, Madison, Wisconsin, USA) ) containing a UGA/TGA stop codon (labeled PTC) after base pair positions 195 (Luc_V2_R3) or 474 (Luc_V3_R3) .
  • Modified NanoLuc protein coding-genes containing the GGA (glycine) codon after base pair positions 195 or 474 were used as corresponding controls for Luc_V2_R3 and Luc_V3_R3, respectively.
  • FIGS. 1B-1C show results from two versions (Luc_V2_R3, shown in FIG.
  • FIG. 1C Luc_V3_R3, shown in FIG. 1C) of a NanoLuc luciferase assay as described in FIG. 1A on engineered suppressor tRNAs R3-1, R3-2, R3-3, R3-4, R3-5, R3-6, R3-7, R3-8, R3-9, R3-10, R3-11, R3-12, R3-13, R3-14, R3-15, R3-147, R3-148, R3-149, R3-150 and R3-151 and positive controls V2_R4, and V3_R4, respectively, as described in Example 1.
  • the engineered tRNA tested is indicated on the x-axis.
  • the measured luciferase activity in relative luminescence unit (RLU) is indicated on the y-axis. Error bars indicate the standard deviation of biological triplicates.
  • FIGS. 1D-1G illustrate the PTC suppression efficiency of engineered tRNAs at both the protein and mRNA levels in cell lines with PTCs in the p53 gene.
  • FIGS. 1D-1E show Western Blots of rescued full-length p53 expression (top row) compared to truncated p53 expression (middle row) and GAPDH expression (bottom row) in DMS1114 cells (FIG. 1D) or Calu6 cells (FIG.
  • FIGS. 1F-1G show RT-qPCR results of the level of the premature UGA stop codon-containing p53 mRNA in DMS1114 cells (FIG. 1F) or Calu6 cells (FIG.
  • FIGS. 1I-1O present results from next-generation tRNA sequencing, detailing the expression levels of engineered tRNAs (FIGS. 1I-1J) , their corresponding endogenous tRNAs (FIG. 1K) , and the homeostasis of the endogenous tRNAome (FIGS. 1L-1O) .
  • FIGS. 1I-1K feature line plots that show the normalized total reads detected for selected engineered and endogenous tRNAs across different samples. The horizontal axes represent the SRocl positions from the 5’ to 3’ ends of the reference tRNAs, while the vertical axes display normalized total read counts. Each line in these plots (FIGS.
  • 1I-1K corresponds to a sample: Luc_V2_R3 cell line transfected with plasmids expressing engineered tRNAs (R3-8, black dashed line; R3-147, black solid line; R3-147-M54, black dotted line) , with Scr1-4 (grey solid line) used as a negative control, and cells treated with H 2 O (grey dashed line) used as a blank control.
  • the reference sequence to which the reads are aligned is indicated at the top of each plot, including R3-8 (FIG. 1I, left panel, from naturally occurring tRNA Arg-CCT-4-1) , R3-147 (FIG.
  • FIGS. 1L-1O compare endogenous tRNA expression levels between Luc_V2_R3 cell lines transfected with Scr1-4 (plotted on all y-axes) and various engineered tRNAs (plotted on all x-axes) , including R3-8 (FIG. 1L) , R3-147 (FIG.
  • FIG. 1M Total normalized read counts are shown on each axis in log10 format.
  • the Pearson correlation coefficient for each comparison is displayed in the top left of each panel.
  • Each figure (FIGS. 1L-1O) is divided into three panels: the left panel shows the analysis of all cytoplasmic tRNAs at the single tRNA level, the middle panel presents the isodecoder level analysis, and the right panel focuses on the isoacceptor level analysis.
  • FIG. 1P displays Western blot results for the modified NanoLuc protein rescued by various engineered tRNAs.
  • WCE denotes the whole cell extract, which serves as a loading control to confirm the presence and enrichment of the targeted NanoLuc protein.
  • FT refers to the flow-through sample collected during immunoprecipitation, used to assess the success of the immunoprecipitation, while “IP” indicates the immunoprecipitated sample.
  • the engineered tRNAs R3-8, R3-147 and R3-147-M54 (referred to as M54) were transfected with plasmids and expressed in the LUC_V2_R3 cell line. The upper band represents the rescued NanoLuc protein, as shown in FIG.
  • FIGS. 1Q-1S present the results of NanoLuc luciferase assays (left panel) and transduction efficiency (right panel, measured by the proportion of cells exhibiting GFP expression) for the Luc-V2-R3 cell line, which was transduced with lentivirus (denoted as "LV” in the bar plot) carrying engineered tRNA genes, including R3-5 (FIG. 1Q) , R3-8 (FIG. 1R) , and R3-147 (FIG. 1S) . Two different MOIs (multiplicities of infection) of the lentivirus were used, as indicated on the x-axis.
  • the y-axes of the bar plot in the left panel show relative luminescence units, while the y-axes of the bar plot in the right panel display the percentage of GFP-positive (GFP+) cells.
  • Error bars represent the standard deviation from biological triplicates. A blank control was also performed with no lentivirus transduction.
  • FIGS. 1AA-1BB illustrate the construct schematic of recombinant Adeno-Associated Virus (rAAV) and the results of NanoLuc luciferase assays in the Luc-V2-R3 cell line transduced with rAAV carrying engineered suppressor tRNA.
  • rAAV Adeno-Associated Virus
  • FIG. 1AA presents the schematic of an scAAV-1xU6 vector, which includes, from left to right (5’ to 3’ direction) : a mutated inverted terminal repeat (AAV2 ⁇ ITR) , a U6 cassette (comprising the U6 promoter, an engineered tRNA, and a poly-T termination signal) , the human cytomegalovirus (CMV) enhancer, the chicken ⁇ -actin promoter, the reporter gene mCherry, and a normal AAV2 ITR.
  • FIG. 1BB shows the results of NanoLuc luciferase assays for cells transduced with rAAV containing engineered suppressor tRNA genes in the scAAV-1xU6 vector, as depicted in FIG.
  • FIG. 1H shows the results of NanoLuc luciferase assay as described in FIG. 1A, comparing the engineered tRNAs M2, M3, M4, M5, M6, M7, and M8 with R3-147 (left-most bar) , water (right-most bar) , Scr1-4, and G418 (3rd bar from the right) in the Luc-V2-R3 cell line.
  • the x-axis indicates the sample identity
  • the y-axis indicates the measured luciferase activity in relative luminescence unit (RLU) .
  • Error bars indicate the standard deviation from biological triplicates.
  • FIGS. 1T-1Z present results from next-generation tRNA sequencing, detailing the expression levels of engineered tRNAs (FIGS. 1T-1U) , their corresponding endogenous tRNA (FIG. 1V) , scrambled sequence (FIG. 1U, right panel) , and the homeostasis of the endogenous tRNAome (FIGS. 1W-1Z) .
  • FIGS. 1T-1V illustrate line plots showing the normalized total reads detected for selected engineered and endogenous tRNAs across different samples. The horizontal axes represent the SRocl positions from the 5’ to 3’ ends of the reference tRNAs, while the vertical axes display normalized total read counts. Each line in these plots (FIGS.
  • 1T-1V corresponds to a sample: Luc_V2_R3 cell line transfected with plasmids expressing engineered tRNAs (R3-147, grey solid line; M2, black solid line; M3, black dashed line; M4, black dotted line) , with Scr1-4 (grey dotted line) used as a negative control.
  • the reference sequence to which the reads are aligned is indicated at the top of each plot, including R3-147 (FIG. 1T, left panel) , M2 (FIG. 1T, right panel) , M4 (FIG. 1U, left panel) , scrambled sequence Scr1-4 (FIG.
  • FIGS. 1W-1Z compare endogenous tRNA expression levels between Luc_V2_R3 cell lines transfected with Scr1-4 (plotted on all y-axes) and various engineered tRNAs (plotted on all x-axes) , including R3-147 (FIG. 1W) , M2 (FIG. 1X, also referred to as R3-147-M2) , M3 (FIG. 1Y, also referred to as R3-147-M3) , and M4 (FIG.
  • FIG. 1Z also referred to as R3-147-M4 .
  • Total normalized read counts are shown on each axis in log10 format.
  • the Pearson correlation coefficient for each comparison is displayed in the top left of each panel.
  • Each figure (FIGS. 1W-1Z) is divided into three panels: the left panel shows the analysis of all cytoplasmic tRNAs at the single tRNA level, the middle panel presents the isodecoder level analysis, and the right panel focuses on the isoacceptor level analysis.
  • FIGS. 2A-2DD show schematics of the secondary structures of human native tRNA Arg-TCT-1-1 (HGNC: 34695, NCBI Gene: 100189133, corresponding to the sequence set forth in SEQ ID NO: 43) (FIG. 2A) and its derived engineered tRNAs (FIGS. 2B-2DD) .
  • Each panel depicts the secondary structure of the respective tRNA, with A, G, C, and U representing the relative positions of the bases adenine (A) , guanine (G) , cytosine (C) , and uracil (U) , dots representing pairing between bases, and numbers indicating the SRocl position of the sequence from 5’ to 3’ .
  • the T-arm is shown to the right
  • the D-arm is shown to the left
  • the anticodon arm is shown at the bottom (with the tri-nucleotide anticodon comprising the three bases at the bottom of each schematic and underlined)
  • the acceptor arm is shown at the top.
  • the arrow in FIG. 2B indicates the change in R3-147 compared to human tRNA Arg-TCT-1-1.
  • the nucleotide “A” on the 3’side of the anticodon (at SRocl position 36) in FIGS. 2B-2DD indicates that the nucleotide at that position has been changed from U to A in the respective engineered tRNA compared to human tRNA Arg-TCT-1-1.
  • FIG. 2A shows human tRNA Arg-TCT-1-1 (corresponding to the sequence set forth in SEQ ID NO: 43) .
  • FIG. 2B shows engineered tRNA R3-147 (corresponding to the sequence set forth in SEQ ID NO: 1) , which has the same sequence as human tRNA Arg-TCT-1-1 except that R3-147 has a UCA anticodon instead of the UCU anticodon present in human tRNA Arg-TCT-1-1.
  • FIG. 2A shows human tRNA Arg-TCT-1-1 (corresponding to the sequence set forth in SEQ ID NO: 43) .
  • FIG. 2B shows engineered tRNA R3-147 (corresponding to the sequence set forth in SEQ ID NO: 1) , which has the same sequence as human tRNA Arg-TCT-1-1 except that R3-147 has a UCA anticodon instead of the UCU anticodon present in human tRNA Arg-TCT-1-1.
  • FIG. 2C shows engineered tRNA M2 (corresponding to the sequence set forth in SEQ ID NO: 2, also referred to as R3-147-M2) , which has the same sequence as R3-147 except that it contains a C at SRocl position 40, corresponding to a U to C substitution at the 4th nucleotide 3’ to the anticodon compared to R3-147.
  • FIG. 2D shows engineered tRNA M3 (corresponding to the sequence set forth in SEQ ID NO: 3, also referred to as R3-147-M3) , which has the same sequence as R3-147 except that it contains a CCA sequence attached to the acceptor arm at the 3’ end.
  • FIG. 2E shows engineered tRNA M4 (corresponding to the sequence set forth in SEQ ID NO: 4, also referred to as R3-147-M4) , which has the same sequence as R3-147 except that it contains a G at SRocl position 37, corresponding to an A to G substitution at the 1st nucleotide 3’ to the anticodon compared to R3-147.
  • FIG. 2F shows engineered tRNA M5 (corresponding to the sequence set forth in SEQ ID NO: 5, also referred to as R3-147-M5) , which contains both the M2 and M3 substitutions.
  • FIG. 2G shows engineered tRNA M6 (corresponding to the sequence set forth in SEQ ID NO: 6, also referred to as R3-147-M6) , which contains both the M2 and M4 substitutions.
  • FIG. 2H shows engineered tRNA M7 (corresponding to the sequence set forth in SEQ ID NO: 7, also referred to as R3-147-M7) , which contains both the M3 and M4 substitutions.
  • FIG. 2I shows engineered tRNA M8 (corresponding to the sequence set forth in SEQ ID NO: 8, also referred to as R3-147-M8) , which contains all three of the M1, M2, and M3 substitutions.
  • FIG. 2J shows engineered tRNA M22 (corresponding to the sequence set forth in SEQ ID NO: 65, also referred to as R3-147-M22) , which contains the M2 substitutions.
  • FIG. 2K shows engineered tRNA M23 (corresponding to the sequence set forth in SEQ ID NO: 66, also referred to as R3-147-M23) , which contains the M2 substitutions.
  • FIG. 2L shows engineered tRNA M24 (corresponding to the sequence set forth in SEQ ID NO: 67, also referred to as R3-147-M24) , which contains the M2 substitutions.
  • FIG. 2M shows engineered tRNA M25 (corresponding to the sequence set forth in SEQ ID NO: 68, also referred to as R3-147-M25) , which contains the M2 substitutions.
  • FIG. 2N shows engineered tRNA M26 (corresponding to the sequence set forth in SEQ ID NO: 69, also referred to as R3-147-M26) , which contains the M2 substitutions.
  • FIG. 2O shows engineered tRNA M46 (corresponding to the sequence set forth in SEQ ID NO: 70, also referred to as R3-147-M46) , which contains the M2 substitutions.
  • FIG. 2P shows engineered tRNA M50 (corresponding to the sequence set forth in SEQ ID NO: 71, also referred to as R3-147-M50) , which contains the M2 substitutions.
  • FIG. 2Q shows engineered tRNA M54 (corresponding to the sequence set forth in SEQ ID NO: 72, also referred to as R3-147-M54) , which contains the M2 substitutions.
  • FIG. 2R shows engineered tRNA M55 (corresponding to the sequence set forth in SEQ ID NO: 73, also referred to as R3-147-M55) , which contains the M2 substitutions.
  • FIG. 2S shows engineered tRNA M56 (corresponding to the sequence set forth in SEQ ID NO: 74, also referred to as R3-147-M56) , which contains the M4 substitutions.
  • FIG. 2T shows engineered tRNA M57 (corresponding to the sequence set forth in SEQ ID NO: 75, also referred to as R3-147-M57) , which contains the M2 substitutions.
  • FIG. 2U shows engineered tRNA M58 (corresponding to the sequence set forth in SEQ ID NO: 76, also referred to as R3-147-M58) , which contains the M2 substitutions.
  • FIG. 2V shows engineered tRNA M59 (corresponding to the sequence set forth in SEQ ID NO: 77, also referred to as R3-147-M59) , which contains the M2 substitutions.
  • FIG. 2W shows engineered tRNA M62 (corresponding to the sequence set forth in SEQ ID NO: 78, also referred to as R3-147-M62) , which contains the M2 substitutions.
  • FIG. 2X shows engineered tRNA M63 (corresponding to the sequence set forth in SEQ ID NO: 79, also referred to as R3-147-M63) , which contains the M2 substitutions.
  • FIG. 2Y shows engineered tRNA M65 (corresponding to the sequence set forth in SEQ ID NO: 80, also referred to as R3-147-M65) , which contains the M2 substitutions.
  • FIG. 2Z shows engineered tRNA M67 (corresponding to the sequence set forth in SEQ ID NO: 81, also referred to as R3-147-M67) , which contains the M2 substitutions.
  • FIG. 2AA shows engineered tRNA M100 (corresponding to the sequence set forth in SEQ ID NO: 61, also referred to as R3-147-M100) , which contains the M2 substitutions.
  • 2BB shows engineered tRNA M102 (corresponding to the sequence set forth in SEQ ID NO: 62, also referred to as R3-147-M102) , which contains the M2 substitutions.
  • FIG. 2CC shows engineered tRNA M103 (corresponding to the sequence set forth in SEQ ID NO: 63, also referred to as R3-147-M103) , which contains the M2 substitutions.
  • FIG. 2DD shows engineered tRNA M108 (corresponding to the sequence set forth in SEQ ID NO: 64, also referred to as R3-147-M108) , which contains the M4 substitutions.
  • FIGS. 3A and 3B show schematics of the secondary structures of engineered tRNAs. Each panel depicts the secondary structure of the respective tRNA, with A, G, C, and U representing the relative positions of the bases adenine (A) , guanine (G) , cytosine (C) , and uracil (U) , dots representing pairing between bases, and numbers indicating the SRocl position of the sequence from 5’ to 3’ .
  • A adenine
  • G guanine
  • C cytosine
  • U uracil
  • FIG. 3A shows engineered tRNA R3-5 (corresponding to the sequence set forth in SEQ ID NO: 13) , which has the same sequence as human tRNA Arg-CCT-1-1 (corresponding to the sequence set forth in SEQ ID NO: 32) except that R3-5 has a UCA anticodon instead of the CCU anticodon present in human tRNA Arg-CCT-1-1.
  • FIG. 13 shows engineered tRNA R3-5 (corresponding to the sequence set forth in SEQ ID NO: 13) , which has the same sequence as human tRNA Arg-CCT-1-1 (corresponding to the sequence set forth in SEQ ID NO: 32) except that R3-5 has a UCA anticodon instead of the CCU anticodon present in human tRNA Arg-CCT-1-1.
  • FIG. 3B shows engineered tRNA R3-8 (corresponding to the sequence set forth in SEQ ID NO: 16) , which has the same sequence as human tRNA Arg-CCT-4-1 (corresponding to the sequence set forth in SEQ ID NO: 35) except that R3-8 has a UCA anticodon instead of the CCU anticodon present in human tRNA Arg-CCT-4-1.
  • FIG. 4A presents the results of a NanoLuc luciferase assay, as described in FIG. 1A, comparing engineered tRNAs with the positive control R3-147 and the negative control Scr1-4.
  • the vertical axis shows the fold change in relative luminescence unit for cell lines Luc-V2-R3 transfected with plasmids expressing the engineered suppressor tRNAs (shown on the horizontal axis) compared to a cell line transfected with plasmids expressing tRNA R3-147. Error bars indicate the standard deviation of biological triplicates.
  • the horizontal dotted line represents a fold change of 1.
  • FIGS. 4B-4C illustrate the outcomes of PTC readthrough assessments on X-linked Alport syndrome-associated PTC mutants within the gene COL4A5 (Collagen alpha-5 (IV) ) treated with lentivirus (referred to as "LV” in the bar plot) containing various engineered tRNAs.
  • the PTC mutations were introduced into the A549 cell line, resulting in a conversion from an arginine codon to a stop codon at positions 1563 ( “COL4A5 R1563*” ) (FIG. 4B, left panel) and 373 ( “COL4A5 R373*” ) (FIG. 4B, right panel) within the COL4A5 protein sequence (NCBI Reference Sequence: NP_000486.1) .
  • RT-qPCR results show the relative levels of COL4A5 mRNA in samples treated with engineered suppressor tRNAs R3-147 and R3-147-M54 transduced by lentivirus, as indicated on the x-axes.
  • the mRNA levels of COL4A5 in each sample were normalized to the mRNA level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and plotted as fold changes relative to the WT sample (A549 cell) on the y-axes.
  • GPDH glyceraldehyde-3-phosphate dehydrogenase
  • “Blank” indicates a negative control where the PTC cells are untreated with the lentivirus. Error bars represent the standard deviation of biological triplicates.
  • 4C presents the integrated density of the COL4A5 signal normalized to cell counts in immunofluorescence analysis, showing the restoration of full-length COL4A5 protein in the COL4A5 R373*PTC cell line treated with lentivirus containing engineered suppressor tRNA R3-147-M54, as indicated on the x-axes.
  • "Blank” refers to a negative control where PTC cells are untreated with the lentivirus. Cells treated solely with the secondary antibody are included to confirm that the observed signal is due to nonspecific binding.
  • FIGS. 4D-4F illustrate the construct schematic of recombinant Adeno-Associated Virus (rAAV) and the results of NanoLuc luciferase assays in the Luc-V2-R3 cell line transduced with rAAV carrying engineered suppressor tRNA.
  • rAAV Adeno-Associated Virus
  • FIGS. 4D presents the schematic of an ssAAV-2xU6 vector, which contains, from left to right (5’ to 3’ direction) : an Adeno-associated virus inverted terminal repeat (AAV2 ITR) , two identical copies of a U6 cassette (including the U6 promoter, an engineered tRNA, and a poly-T termination signal) , the human cytomegalovirus (CMV) enhancer, the chicken ⁇ -actin promoter, the reporter gene mCherry, a poly A signal, and another AAV2 ITR.
  • AAV2 ITR Adeno-associated virus inverted terminal repeat
  • U6 cassette including the U6 promoter, an engineered tRNA, and a poly-T termination signal
  • CMV human cytomegalovirus
  • 4E-4F show NanoLuc luciferase assay results (left panel) and transduction efficiency (right panel, via measurement of the proportion of cells showing mCherry expression) for cells transduced with rAAV containing engineered suppressor tRNA genes in the ssAAV-2xU6 vector, as shown in FIG. 4D.
  • Various gradient MOIs (multiplicity of infection) of the rAAVs were transduced into the Luc-V2-R3 cell line, as indicated on the x-axes, increasing from right to left.
  • the relative luminescence units are shown on the y-axes of the bar plot in the left panel, and the percentage of mCherry-positive cells is shown on the y-axes of the bar plot in the right panel.
  • the strand type and serotype of the AAV are indicated at the bottom of the bar plot.
  • the specific engineered suppressor tRNA genes used in the assay are indicated at the bottom of the bar plot, including R3-147 (FIG. 4E) and R3-147-M54 (FIG. 4F) .
  • Error bars represent the standard deviation of biological triplicates.
  • FIGS. 4G-4H depict the relative levels of urinary proteins in male mice with X-linked Alport syndrome, injected with ssAAV2/9 containing the construct detailed in FIG. 4D.
  • These mice possess an X-linked COL4A5 premature termination codon (PTC) mutation at position 471 (arginine to PTC) ( “COL4A5-R471*” ) within the COL4A5 protein sequence (NCBI Reference Sequence: NP_000486.1) .
  • the ratio of urine albumin (U-ALB) to urine creatinine (U-CRE) an indicator of disease progression, is plotted on the y-axis, while the age of the mice in weeks is plotted on the x-axis.
  • U-ALB urine albumin
  • U-CRE urine creatinine
  • mice injected with saline are shown with a grey solid line
  • those injected with rAAV are shown with a grey solid line
  • those injected with rAAV are shown with a grey solid line
  • those injected with rAAV are shown with a grey solid line
  • those injected with rAAV are shown with a grey solid line
  • those injected with rAAV are shown with a grey solid line
  • the intravenous injection is performed at 4 weeks of age, as indicated by the arrow below the line plot. Error bars represent the standard deviation of replicates.
  • the present application provides novel engineered arginine-carrying tRNA for suppressing a premature UGA/TGA stop codon (also referred to herein as “engineered suppressor tRNAs” ) .
  • engineered suppressor tRNAs contain one or more modifications relative to a suppressor tRNA identified through extensive screening as being particularly efficient in suppressing UGA/TGA stop codons.
  • the modifications include, for example, i) an A to G substitution at the 1st nucleotide 3’ to the anticodon; ii) a U to C substitution at the 4th nucleotide 3’ to the anticodon; and iii) a CCA sequence attached to the acceptor arm at the 3’ end introduced through a nucleic acid encoding the suppressor tRNA.
  • the one or more modifications introduced to the suppressor tRNA result in a further increase in readthrough efficiency, making the modified tRNAs particularly suitable for suppressing premature stop codons in vivo.
  • a 3’ CCA sequence is added to the acceptor arm of a tRNA post-transcriptionally.
  • the present application in one aspect provides engineered tRNAs for carrying an arginine comprising a T-arm, a D-arm, an anticodon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises one or more modifications relative to a tRNA having the sequence of SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16; and wherein the one or more modifications comprises: i) an A to G substitution at the 1 st nucleotide 3’ to the anticodon; ii) a U to C substitution at the 4 th nucleotide 3’ to the anticodon; and/or iii) a CCA sequence attached to the acceptor arm at the 3’ end.
  • nucleic acids encoding the engineered tRNA as well as expression cassettes and vectors comprising such nucleic acids. Also provided are methods of using the engineered tRNAs, nucleic acids encoding the engineered tRNAs, expression cassettes, and vectors.
  • transfer ribonucleic acid refers to a nucleic acid molecule that helps translate mRNA to protein.
  • anti codon refers to an amino acid corresponding to the mRNA codon that is recognized by the tRNA’s anticodon.
  • Charge can be mediated by aminoacyl tRNA synthetase.
  • premature stop codon , “premature termination codon” , and “PTC” are used synonymously herein to refer to a stop codon that, when present, results in an unintended truncation of a polypeptide relative to a wild-type counterpart.
  • engineered tRNA can refer to transfer RNAs having at least one difference in the sequence of the engineered tRNA relative to a comparable wild type tRNA, such as, for example, relative to human tRNA Arg-TCT-1-1.
  • siRNA suppressor or “engineered tRNA suppressor” as used herein refer to an engineered tRNA capable of suppressing premature stop codon halt in an mRNA.
  • restoring as used herein in relation to expression of a protein can refer to the ability to establish expression of the full-length version of the protein from an mRNA comprising a PTC, where previous protein expression was truncated due to the PTC.
  • mutation can refer to an alteration to a nucleic acid sequence and/or a polypeptide sequence relative to a reference sequence.
  • disease refers to one or more characteristics of a mammalian cell that results from a stop codon within the coding region of a gene inside the cell (e.g., that results from a nonsense mutation) .
  • transduction of cells refers to the process of transferring nucleic acid into a cell using a DNA or RNA virus rather than by transfection.
  • An RNA virus i.e., a retrovirus
  • Exogenous genetic material contained within a retrovirus is incorporated into the genome of the transduced cell.
  • a cell that has been “transduced” with a chimeric DNA virus does not incorporate the exogenous genetic material into its genome but can express the exogenous genetic material extra-chromosomally within the cell.
  • a “transduced gene” is a gene that has been introduced into the cell via retroviral or vector infection and provirus integration.
  • expression cassette refers to a nucleic acid sequence capable of directing expression of a particular nucleotide sequence in an appropriate host cell.
  • operably-linked refers to the association of nucleic acid sequences on single nucleic acid fragment such that the function of one of the sequences is affected by another.
  • a regulatory DNA sequence is considered “operably linked to” or “associated with” a DNA sequence that codes for an RNA or a polypeptide when the two sequences are situated such that the regulatory DNA sequence affects expression of the coding DNA sequence (i.e., that the coding sequence or functional RNA is under the transcriptional control of the promoter) .
  • nucleic acid generally refers to a polymer comprising one or more nucleic acid subunits or nucleotides.
  • a nucleic acid may include one or more subunits selected from adenosine (A) , cytosine (C) , guanine (G) , thymine (T) and uracil (U) , or variants thereof.
  • a nucleotide can include A, C, G, T or U, or variants thereof.
  • a nucleotide can include any subunit that can be incorporated into a growing nucleic acid strand.
  • Such subunit can be an A, C, G, T, or U, or any other subunit that is specific to one or more complementary A, C, G, T or U, or complementary to a purine (e.g., A or G, or variant thereof) or a pyrimidine (e.g., C, T or U, or variant thereof) .
  • a subunit can enable individual nucleic acid bases or groups of bases (e.g., AA, TA, AT, GC, CG, CT, TC, GT, TG, AC, CA, or uracil-counterparts thereof) to be resolved.
  • a nucleic acid is deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) , or derivatives thereof.
  • a nucleic acid may be single-stranded or double-stranded.
  • nucleic acid molecule a nucleic acid sequence or a nucleotide sequence as used herein generally refer to polymeric forms of nucleotides of any length, either ribonucleotides or deoxyribonucleotides, with a given sequence of nucleotides, of which it may be desired to know the presence or amount.
  • this term comprises, but is not limited to, single-, double-, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or a polymer comprising purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases.
  • the backbone of the polynucleotide can comprise sugars and phosphate groups (as may typically be found in RNA or DNA) , or modified or substituted sugar or phosphate groups.
  • the nucleotide sequence can comprise RNA or DNA, or a sequence derived from RNA or DNA. Examples of nucleotide sequences are sequences corresponding to natural or synthetic RNA or DNA including genomic DNA and messenger RNA.
  • sequencing generally refers to methods and technologies for determining the sequence of nucleotide bases in one or more polynucleotides.
  • the polynucleotides can be, for example, nucleic acid molecules such as DNA or RNA, including variants or derivatives thereof (e.g., single stranded DNA) .
  • Sequencing can be performed by various systems currently available, such as, without limitation, a sequencing system by Sanger sequencing, Pacific Biosciences Oxford or Life Technologies (Ion ) .
  • sequencing may be performed using nucleic acid amplification, polymerase chain reaction (PCR) (e.g., digital PCR, quantitative PCR, or real time PCR) , or isothermal amplification.
  • PCR polymerase chain reaction
  • Such systems may provide a plurality of raw genetic data corresponding to the genetic information of a subject (e.g., human) , as generated by the systems from a sample provided by the subject.
  • treatment or “treating” are used in reference to a pharmaceutical or other intervention regimen for obtaining beneficial or desired results in the recipient, including but not limited to one or more therapeutic benefits and/or prophylactic benefits.
  • a “therapeutic benefit” in this sense can refer to eradication or amelioration of symptoms or of an underlying disorder being treated.
  • a “prophylactic effect” in this sense includes delaying, preventing, or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof, even though a diagnosis of this disease may not have been made.
  • Transfer RNAs are generally RNA molecules of about 70-90 nucleotides in length. They fold into a clover leaf-like secondary structure that contains three hairpin loop “arms” and an acceptor arm comprising the 3’ and 5’ ends of the tRNA.
  • a tRNA includes: a D-stem with a D-loop at the end of the stem, an anticodon stem with an anticodon loop at the end of the stem (comprising a tri-nucleotide anti-codon sequence) , a variable region, and a T-stem with a T-loop at the end of the stem. The anticodon recognizes the corresponding codon on the mRNA.
  • the 3’ CCA is usually not present in the DNA sequence encoding the tRNA in mammalian cells, but is rather added post-transcriptionally.
  • tRNAs serve as adaptors to link an mRNA and its protein products by both recognizing the codons on mRNA and carrying the amino acid to append to the peptide chain. Upon recognition of the codon corresponding to its anticodon, a charged tRNA can transfer its amino acid to the growing amino acid chain to form a polypeptide or protein. Endogenous tRNAs can be charged by endogenous aminoacyl tRNA synthetase.
  • tRNA biogenesis entails multiple steps, including transcription by a polymerase into a precursor tRNA (pre-tRNA) and subsequent intron splicing by a splicing endonuclease (for tRNAs containing introns; not every tRNA has an intron) , 5’ end and 3’ end cleavage by endo-and/or exonucleases, addition of the CCA tail by nucleotidyltransferase, and modifications on multiple nucleotide residues (Sekulovski S, Trowitzsch S. Transfer RNA processing -from a structural and disease perspective. Biol Chem. 2022 Jun 21;403 (8-9) : 749-763.
  • the canonical Sblul position system assigns numbers to each nucleotide based on the tRNA cloverleaf secondary structure. Nucleotides in positions 1-7 pair with those in positions 72-66 to form the acceptor arm. Positions 8-9 act as spacers between the acceptor arm and the D-arm. Nucleotides in positions 10-13 pair with those in positions 25-22 to form the D-stem, while the D-loop consists of nucleotides from positions 14 to 21 (if a tRNA has more than 8 nucleotides in the D-loop, the positions are listed as 14-17, 17A, 18, 19, 20, 20A, 20B, 21, depending on the tertiary structure) .
  • Position 26 serves as a spacer between the D-arm and the anticodon arm. Nucleotides in positions 27-31 pair with those in positions 43-39 to form the anticodon stem.
  • the anticodon loop includes nucleotides from positions 32 to 38, with the anticodon located at positions 34-36.
  • the variable region consists of nucleotides from positions 44 to 48 (if a tRNA has more than 5 nucleotides in the variable region, the positions are listed as 44, 45, e11-e17, e1-e5, e27-e21, 46, 47, 48) .
  • the present invention provides engineered tRNAs for carrying an arginine comprising a T-arm, a D-arm, an anticodon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises one or more modifications relative to a tRNA having the sequence of SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16; and wherein the one or more modifications comprises: i) an A to G substitution at the 1 st nucleotide 3’ to the anticodon;
  • the engineered tRNA has a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1.
  • the engineered tRNA contains no more than 12 (such as no more than about any of 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the engineered tRNA has a nucleotide sequence that is at least about 80% (e.g., at least about any of 85%, 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1.
  • the engineered tRNA has a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA has a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 16.
  • the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16.
  • an engineered tRNA for carrying an arginine comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises an A to G substitution at the 1 st nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1.
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16. In some embodiment, the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 4.
  • an engineered tRNA for carrying an arginine comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises a U to C substitution at the 4th nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1.
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16. In some embodiment, the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 2.
  • an engineered tRNA for carrying an arginine comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm
  • the anticodon-arm comprises a tri-nucleotide anti-codon
  • the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon
  • the engineered tRNA comprises a CCA sequence attached to the acceptor arm at the 3’ end (e.g., introduced through a nucleic acid encoding the suppressor tRNA or in an isolated tRNA) .
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16. In some embodiment, the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 3.
  • an engineered tRNA for carrying an arginine comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm
  • the anticodon-arm comprises a tri-nucleotide anti-codon
  • the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon
  • the engineered tRNA comprises an A to G substitution at the 1 st nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1 and a U to C substitution at the 4th nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1.
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, or 2) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiment, the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 6.
  • an engineered tRNA for carrying an arginine comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm
  • the anticodon-arm comprises a tri-nucleotide anti-codon
  • the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon
  • the engineered tRNA comprises an A to G substitution at the 1 st nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1 and a CCA sequence attached to the acceptor arm at the 3’ end (e.g., introduced through a nucleic acid encoding the suppressor tRNA or in an isolated tRNA) .
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16. In some embodiment, the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 7.
  • an engineered tRNA for carrying an arginine comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm
  • the anticodon-arm comprises a tri-nucleotide anti-codon
  • the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon
  • the engineered tRNA comprises a U to C substitution at the 4 th nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1 and a CCA sequence attached to the acceptor arm at the 3’ end (e.g., introduced through a nucleic acid encoding the suppressor tRNA or in an isolated tRNA) .
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16. In some embodiment, the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 5.
  • an engineered tRNA for carrying an arginine comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm
  • the anticodon-arm comprises a tri-nucleotide anti-codon
  • the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon
  • the engineered tRNA comprises an A to G substitution at the 1 st nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1, and a U to C substitution at the 4th nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1, and a CCA sequence attached to the acceptor arm at the 3’ end (e.g., introduced through a nucleic acid encoding the suppressor tRNA or in in isolated tRNA) .
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1.
  • the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13.
  • the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16.
  • the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, or 2) nucleotide substitutions relative to SEQ ID NO: 1.
  • the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 8.
  • an engineered tRNA for carrying an arginine comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm
  • the anticodon-arm comprises a tri-nucleotide anti-codon
  • the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon
  • the engineered tRNA comprises a U to A substitution at the 7th nucleotide 5’ to the anticodon, a U to C substitution at the 4th nucleotide 3’ to the anticodon, an A to U substitution at the 7th nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1, and a CCA sequence attached to the acceptor arm at the 3’ end (e.g., introduced through a nucleic acid encoding the suppressor tRNA or in in isolated tRNA) .
  • the engineered tRNA comprises a U to A substitution at position 27, a U to C substitution at position 40, and an A to U substitution at position 43 relative to a tRNA having the sequence of SEQ ID NO: 1, wherein positions are labeled according to SRocl position.
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1.
  • the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, or 2) nucleotide substitutions relative to SEQ ID NO: 1.
  • the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16. In some embodiment, the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 61.
  • an engineered tRNA for carrying an arginine comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm
  • the anticodon-arm comprises a tri-nucleotide anti-codon
  • the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon
  • the engineered tRNA comprises a G to U substitution at the 5th nucleotide 5’ to the anticodon, a U to C substitution at the 4th nucleotide 3’ to the anticodon, a C to A substitution at the 5th nucleotide 3’ to the anticodon, an A to G substitution at the 7th nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1, and a CCA sequence attached to the acceptor arm at the 3’ end (e.g., introduced through a nucleic acid encoding the suppress
  • the engineered tRNA comprises a G to U substitution at position 29, a U to C substitution at position 40, a C to A substitution at position 41, and an A to G substitution at position 43 relative to a tRNA having the sequence of SEQ ID NO: 1, wherein positions are labeled according to SRocl position.
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1.
  • the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, or 2) nucleotide substitutions relative to SEQ ID NO: 1.
  • the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16. In some embodiment, the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 62.
  • an engineered tRNA for carrying an arginine comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm
  • the anticodon-arm comprises a tri-nucleotide anti-codon
  • the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon
  • the engineered tRNA comprises a U to C substitution at the 7th nucleotide 5’ to the anticodon, a U to C substitution at the 4th nucleotide 3’ to the anticodon, an A to G substitution at the 7th nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1, and a CCA sequence attached to the acceptor arm at the 3’ end (e.g., introduced through a nucleic acid encoding the suppressor tRNA or in in isolated tRNA) .
  • the engineered tRNA comprises a U to C substitution at position 27, a U to C substitution at position 40, and an A to G substitution at position 43 relative to a tRNA having the sequence of SEQ ID NO: 1, wherein positions are labeled according to SRocl position.
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1.
  • the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, or 2) nucleotide substitutions relative to SEQ ID NO: 1.
  • the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16. In some embodiment, the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 63.
  • an engineered tRNA for carrying an arginine comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm
  • the anticodon-arm comprises a tri-nucleotide anti-codon
  • the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon
  • the engineered tRNA comprises a G to C substitution at the 32nd nucleotide 5’ to the anticodon, a U to C substitution at the 30th nucleotide 5’ to the anticodon, a C to A substitution at the 28th nucleotide 5’ to the anticodon, an A to G substitution at the 8th nucleotide 5’ to the anticodon, an A to G substitution at the 1st nucleotide 3’ to the anticodon, a G to U substitution at the 31st nucleotide 3’ to the anticodon, an A to G substitution
  • the engineered tRNA comprises a G to C substitution at position 2, a U to C substitution at position 4, a C to A substitution at position 6, A to G substitution at position 26, an A to G substitution at position 37, aG to U substitution at position 67, an A to G substitution at position 69, a U to G substitution at position 71, and a C to U substitution at position 72 relative to a tRNA having the sequence of SEQ ID NO: 1, wherein positions are labeled according to SRocl position.
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1.
  • the engineered tRNA has a nucleotide sequence that is at least about 80% (e.g., at least about any of 85%, 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 12 (such as no more than about any of 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1.
  • the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16. In some embodiment, the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 64.
  • the engineered tRNAs contain modifications at locations in the sequence of the engineered tRNA are described relative to the 5’ to 3’s equence of a tRNA reference sequence, wherein the 5’ end of the reference sequence is position 1.
  • the tRNA reference sequence is human tRNA-Arg-TCT-1-1.
  • the tRNA reference sequence is R3-147 (SEQ ID NO: 1) .
  • an engineered transfer RNA for carrying an arginine comprising a T-arm, a D-arm, an anticodon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises one or more modifications relative to a tRNA having the sequence of SEQ ID NO: 1, and wherein the one or more modifications comprise: i) a G at nucleic acid position 37, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1; ii) a C at nucleic acid position 40, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1; and/or iii) a CCA sequence attached to the acceptor arm at the 3’ end.
  • tRNA transfer RNA
  • the engineered tRNA comprises a G at nucleic acid position 37. In some embodiments the engineered tRNA comprises a C at nucleic acid position 40. In some embodiments, the engineered tRNA comprises a CCA sequence attached to the acceptor arm at the 3’ end.
  • the engineered tRNA comprises a C at the 4th nucleotide 3’ to the anticodon (corresponding to nucleic acid position 40, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) , and a CCA sequence attached to the acceptor arm at the 3’ end.
  • the engineered tRNA has the RNA sequence set forth in SEQ ID NO: 5.
  • the engineered tRNA comprises an A at the 7th nucleotide 5’ to the anticodon (corresponding to nucleic acid position 27, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) , a C at the 4th nucleotide 3’ to the anticodon (corresponding to nucleic acid position 40, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) , a U at the 7th nucleotide 3’ to the anticodon (corresponding to nucleic acid position 43, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) and a CCA sequence attached to the acceptor arm at the 3’ end.
  • the engineered tRNA has the RNA sequence set forth in SEQ ID NO: 61.
  • the engineered tRNA comprises a U at the 5th nucleotide 5’ to the anticodon (corresponding to nucleic acid position 29, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) , a C at the 4th nucleotide 3’ to the anticodon (corresponding to nucleic acid position 40, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) , an A at the 5th nucleotide 3’ to the anticodon (corresponding to nucleic acid position 41, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) , a G at the 7th nucleotide 3’ to the anticodon (corresponding to nucleic acid position 43, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) , and a CCA sequence attached to the acceptor arm at the 3’ end.
  • the engineered tRNA has the RNA
  • the engineered tRNA comprises a C at the 7th nucleotide 5’ to the anticodon (corresponding to nucleic acid position 27, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) a C at the 4th nucleotide 3’ to the anticodon (corresponding to nucleic acid position 40, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) , a G at the 7th nucleotide 3’ to the anticodon (corresponding to nucleic acid position 43, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) , and a CCA sequence attached to the acceptor arm at the 3’ end.
  • the engineered tRNA has the RNA sequence set forth in SEQ ID NO: 63.
  • the engineered tRNA comprises a C at the 32nd nucleotide 5’ to the anticodon (corresponding to nucleic acid position 2, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) , a C at the 30th nucleotide 5’ to the anticodon (corresponding to nucleic acid position 4, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) , an A at the 28th nucleotide 5’ to the anticodon (corresponding to nucleic acid position 6, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) , a G at the 8th nucleotide 5’ to the anticodon (corresponding to nucleic acid position 26, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) , a G at the 1st nucleotide 3’ to the anticodon (corresponding to nucleic acid position 37, wherein the nucleic acid
  • the engineered tRNA comprises a C at the 4th nucleotide 3’ to the anticodon (corresponding to nucleic acid position 40, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) .
  • the engineered tRNA comprises a G at the 1st nucleotide 3’ to the anticodon (corresponding to nucleic acid position 37, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) .
  • the engineered tRNA comprises a C at the 4th nucleotide 3’ to the anticodon (corresponding to nucleic acid position 40, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) and a G at the 1st nucleotide 3’ to the anticodon (corresponding to nucleic acid position 37, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) .
  • the engineered tRNA comprises a CCA sequence attached to the acceptor arm at the 3’ end.
  • the engineered tRNA comprises a C at the 4th nucleotide 3’ to the anticodon (corresponding to nucleic acid position 40, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) and the engineered tRNA has the RNA sequence selected from the group consisting of SEQ ID NOs: 2, 5, 6, 8, 65-69, 70, 71, 72-73, 75-77, 78-79, 80, 81, 61, 62, and 63.
  • the engineered tRNA comprises a G at the 1st nucleotide 3’ to the anticodon (corresponding to nucleic acid position 37, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) and the engineered tRNA has the RNA sequence selected from the group consisting of SEQ ID NOs: 4, 6-8, 74, and 64.
  • the engineered tRNA comprises a C at the 4th nucleotide 3’ to the anticodon (corresponding to nucleic acid position 40, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) and a G at the 1st nucleotide 3’ to the anticodon (corresponding to nucleic acid position 37, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) .
  • the engineered tRNA has the RNA sequence set forth in SEQ ID NO: 6.
  • the engineered tRNA comprises a G at the 1 st nucleotide 3’ to the anticodon (corresponding to nucleic acid position 37, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) , and a CCA sequence attached to the acceptor arm at the 3’ end.
  • the engineered tRNA has the RNA sequence set forth in SEQ ID NO: 7.
  • the engineered tRNA comprises a G at the 1st nucleotide 3’ to the anticodon (corresponding to nucleic acid position 37, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) , a C at the 4th nucleotide 3’ to the anticodon (corresponding to nucleic acid position 40, wherein the nucleic acid position corresponds to the sequence set forth in SEQ ID NO: 1) , and a CCA sequence attached to the acceptor arm at the 3’ end.
  • the engineered tRNA has the RNA sequence set forth in SEQ ID NO: 8.
  • the engineered tRNA has a nucleotide sequence that is at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or more than about 95%identical to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8.
  • the engineered tRNA has a nucleotide sequence that is at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or more than about 95%identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA has a nucleotide sequence that is at least about 85%identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA has a nucleotide sequence that is at least about 85%identical to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8.
  • sequence identity between an engineered tRNA and any of the sequences of SEQ ID NOs: 2, 3, 4, 5, 6, 7, or 8 can be from about 70%to about 80%, from 80%to about 90%, from about 85%to about 95%, from about 90%to about 95%, from about 95%to about 99%.
  • sequence identity between an engineered tRNA and any of the sequences of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, or 8 can be at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more.
  • sequence identity between an engineered tRNA and any of the sequences of SEQ ID NOs: 2, 3, 4, 5, 6, 7, or 8 can be at most about 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, or less.
  • the engineered tRNA has a nucleotide sequence that is at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or more than about 95%identical to SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16. In some embodiments, the engineered tRNA has a nucleotide sequence that is at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or more than about 95%identical to SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16.
  • the engineered tRNA has a nucleotide sequence that is at least about 85%identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA has a nucleotide sequence that is at least about 85%identical to SEQ ID NO: 13. In some embodiments, the engineered tRNA has a nucleotide sequence that is at least about 85%identical to SEQ ID NO: 16. In some embodiments, the engineered tRNA has a nucleotide sequence that is at least about 85%identical to SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, or SEQ ID NO: 64.
  • sequence identity between an engineered tRNA and any of the sequences of SEQ ID NOs: 1, 13, 16, 61, 62, 63, or 64 can be from about 70%to about 80%, from 80%to about 90%, from about 85%to about 95%, from about 90%to about 95%, from about 95%to about 99%.
  • sequence identity between an engineered tRNA and any of the sequences of SEQ ID NOs: 1, 13, 16, 61, 62, 63, or 64 can be at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more.
  • sequence identity between an engineered tRNA and any of the sequences of SEQ ID NOs: 1, 13, 16, 61, 62, 63, or 64 can be at most about 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, or less.
  • the %identity can be measured over a range of 90%of the length of nucleotides of an engineered tRNA. In some embodiments, the %identity can be measured over a range of 95%of the length of nucleotides of an engineered tRNA. In some embodiments, the %identity can be measured over 100%of the length of nucleotides of an engineered tRNA.
  • the engineered tRNA can be a sequence of any of SEQ ID NOs: 2-8, 61, 62, 63, and 64. In some embodiments, the engineered tRNA sequence can comprise any of SEQ ID NOs: 2-8, 61, 62, 63, and 64.
  • the engineered tRNA contains no more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 nucleotide substitutions relative to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, or SEQ ID NO: 64.
  • the engineered tRNA contains no more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 nucleotide substitutions relative to SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16. In some embodiments, the engineered tRNA contains no more than about 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16.
  • the engineered tRNAs described herein can contain further modifications relative to SEQ ID NO: 1 (e.g., further nucleotide substitutions other than those described above) .
  • the modification can be a mutation, such as an insertion, a deletion (such as, for example, deletion of a single nucleotide from the variable loop) , or a substitution of one or more nucleotides.
  • the insertion is an intron of any length in the tRNA.
  • the engineered suppressor tRNA contains an intron that is spliced during tRNA maturation.
  • the intron is of variable length.
  • the modification can be a chemical modification of one or more nucleotides in the sequence of the engineered tRNA.
  • the chemical modification can comprise pseudouridine, inosine, wyosine, wybutosine, an acetyl group, an isopentenyl group, an hydroxy group, a peroxy group, an ribosyl group, a carbamoyl group, a carboxyl group, a methoxy group, a carbonyl group, a methyl group, a dimethyl group, a trimethyl group, a formyl group, a cyano group, a galactosyl group, a glutamyl group, a fluoro group, a methoxyethyl group, an ethyl group, a phosphate group, an amide group, an ester group, an amino group, or one or more additional modifications as described in “Modified residues” (Genesilico, https: //genesilico.
  • the engineered tRNA can comprise a chemical modification comprising a methyl group, a fluoro group, a methoxyethyl group, an ethyl group, a phosphate group, an amide group, an ester group, or any combination thereof.
  • engineered pre-tRNAs that are processed into any of the engineered tRNAs described herein.
  • the engineered tRNA is synthesized exogenously. In some embodiments, the engineered tRNA comprises both DNA and RNA. In some embodiments in which the engineered tRNA comprises both DNA and RNA, the engineered tRNA comprises a single RNA nucleotide among DNA nucleotides, or a single DNA nucleotide among RNA nucleotides. In some embodiments in which the engineered tRNA comprises both DNA and RNA, the engineered tRNA comprises a stretch of DNA and RNA sequence. In some embodiments, the engineered tRNA is transcribed from DNA, or its reverse, complement, or reverse-complement counterpart.
  • the arginine with which the engineered tRNA is charged is detectably labeled to enable detection in vivo.
  • the labeling comprise, for example, click chemistry wherein an azide/alkyne containing unnatural amino acid can be added by the orthogonal tRNA/synthetase pair and, thus, can be detected using alkyne/azide comprising fluorophore or other such molecule.
  • the engineered tRNAs described herein may be encoded by nucleic acids. Accordingly, in some aspects, there is provided a nucleic acid encoding an engineered tRNA described herein.
  • the nucleic acid is an RNA. In some embodiments, the nucleic acid is a tRNA.
  • a nucleic acid encoding an engineered tRNA for carrying an arginine (or an expression cassette comprising such nucleic acid, or a vector (e.g., a viral vector) comprising such expression cassette) , the engineered tRNA comprising a T-arm, a D-arm, an anticodon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises one or more modifications relative to a tRNA having the sequence of SEQ ID NO: 1, and wherein the one or more modifications comprise: i) an A to G substitution at the 1 st nucleotide 3’ to the anticodon; ii) a U to C substitution at the 4 th nucleotide 3’ to the anticodon; and/or iii)
  • the engineered tRNA has a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1.
  • a nucleic acid encoding an engineered pre-tRNAs that is processed into an engineered tRNA for carrying an arginine (or an expression cassette comprising such nucleic acid, or a vector (e.g., a viral vector) comprising such expression cassette) , the engineered tRNA comprising a T-arm, a D-arm, an anticodon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises one or more modifications relative to a tRNA having the sequence of SEQ ID NO: 1, and wherein the one or more modifications comprise: i) an A to G substitution at the 1st nucleotide 3’ to the anticodon; ii) a U to C substitution at the 4th nucleotide 3’ to the antico
  • the matured tRNA derived from engineered pre-tRNA has a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the matured tRNA derived from engineered pre-tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1.
  • a nucleic acid encoding an engineered tRNA for carrying an arginine (or an expression cassette comprising such nucleic acid, or a vector (e.g., a viral vector) comprising such expression cassette) , the engineered tRNA comprising a T-arm, a D-arm, an anticodon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises one or more modifications relative to a tRNA having the sequence of SEQ ID NO: 13, and wherein the one or more modifications comprise: i) an A to G substitution at the 1 st nucleotide 3’ to the anticodon; ii) a U to C substitution at the 4 th nucleotide 3’ to the anticodon; and iii) a
  • the engineered tRNA has a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13.
  • a nucleic acid encoding an engineered pre-tRNAs that is processed into an engineered tRNA for carrying an arginine (or an expression cassette comprising such nucleic acid, or a vector (e.g., a viral vector) comprising such expression cassette) , the engineered tRNA comprising a T-arm, a D-arm, an anticodon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises one or more modifications relative to a tRNA having the sequence of SEQ ID NO: 13, and wherein the one or more modifications comprise: i) an A to G substitution at the 1st nucleotide 3’ to the anticodon; ii) a U to C substitution at the 4th nucleotide 3’ to the antico
  • the matured tRNA derived from engineered pre-tRNA has a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 13. In some embodiments, the matured tRNA derived from engineered pre-tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13.
  • a nucleic acid encoding an engineered tRNA for carrying an arginine (or an expression cassette comprising such nucleic acid, or a vector (e.g., a viral vector) comprising such expression cassette) , the engineered tRNA comprising a T-arm, a D-arm, an anticodon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises one or more modifications relative to a tRNA having the sequence of SEQ ID NO: 16, and wherein the one or more modifications comprise: i) an A to G substitution at the 1 st nucleotide 3’ to the anticodon; ii) a U to C substitution at the 4 th nucleotide 3’ to the anticodon; and/or iii)
  • the engineered tRNA has a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 16. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16.
  • a nucleic acid encoding an engineered pre-tRNAs that is processed into an engineered tRNA for carrying an arginine (or an expression cassette comprising such nucleic acid, or a vector (e.g., a viral vector) comprising such expression cassette) , the engineered tRNA comprising a T-arm, a D-arm, an anticodon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises one or more modifications relative to a tRNA having the sequence of SEQ ID NO: 16, and wherein the one or more modifications comprise: i) an A to G substitution at the 1st nucleotide 3’ to the anticodon; ii) a U to C substitution at the 4th nucleotide 3’ to the antico
  • the matured tRNA derived from engineered pre-tRNA has a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 16. In some embodiments, the matured tRNA derived from engineered pre-tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16.
  • a nucleic acid encoding an engineered tRNA for carrying an arginine (or an expression cassette comprising such nucleic acid, or a vector (e.g., a viral vector) comprising such expression cassette) , the engineered tRNA comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises an A to G substitution at the 1 st nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1.
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the nucleic acid encoding the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 4. In some embodiments, the nucleic acid encoding the engineered tRNA comprises a DNA sequence encoding the nucleotide sequence of SEQ ID NO: 4.
  • a nucleic acid encoding an engineered tRNA for carrying an arginine (or an expression cassette comprising such nucleic acid, or a vector (e.g., a viral vector) comprising such expression cassette) , the engineered tRNA comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises a U to C substitution at the 4th nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1.
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16.
  • the nucleic acid encoding the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 2. In some embodiments, the nucleic acid encoding the engineered tRNA comprises a DNA sequence encoding the nucleotide sequence of SEQ ID NO: 2.
  • a nucleic acid encoding an engineered tRNA for carrying an arginine (or an expression cassette comprising such nucleic acid, or a vector (e.g., a viral vector) comprising such expression cassette) , the engineered tRNA comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises a CCA sequence attached to the acceptor arm at the 3’ end (e.g., introduced through a nucleic acid encoding the suppressor tRNA or in an isolated tRNA) .
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16.
  • the nucleic acid encoding the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 3. In some embodiments, the nucleic acid encoding the engineered tRNA comprises a DNA sequence encoding the nucleotide sequence of SEQ ID NO: 3.
  • a nucleic acid encoding an engineered tRNA for carrying an arginine (or an expression cassette comprising such nucleic acid, or a vector (e.g., a viral vector) comprising such expression cassette) , the engineered tRNA comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises an A to G substitution at the 1 st nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1 and a U to C substitution at the 4th nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1.
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, or 2) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16.
  • the nucleic acid encoding the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 6. In some embodiments, the nucleic acid encoding the engineered tRNA comprises a DNA sequence encoding the nucleotide sequence of SEQ ID NO: 6.
  • a nucleic acid encoding an engineered tRNA for carrying an arginine (or an expression cassette comprising such nucleic acid, or a vector (e.g., a viral vector) comprising such expression cassette) , the engineered tRNA comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises an A to G substitution at the 1 st nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1 and a CCA sequence attached to the acceptor arm at the 3’ end (e.g., introduced through a nucleic acid encoding the suppressor tRNA or in an isolated tRNA) .
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16.
  • the nucleic acid encoding the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 7. In some embodiments, the nucleic acid encoding the engineered tRNA comprises a DNA sequence encoding the nucleotide sequence of SEQ ID NO: 7.
  • a nucleic acid encoding an engineered tRNA for carrying an arginine (or an expression cassette comprising such nucleic acid, or a vector (e.g., a viral vector) comprising such expression cassette) , the engineered tRNA comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises a U to C substitution at the 4 th nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1 and a CCA sequence attached to the acceptor arm at the 3’ end (e.g., introduced through a nucleic acid encoding the suppressor tRNA or in an isolated tRNA) .
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16.
  • the nucleic acid encoding the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 5. In some embodiments, the nucleic acid encoding the engineered tRNA comprises a DNA sequence encoding the nucleotide sequence of SEQ ID NO: 5.
  • a nucleic acid encoding an engineered tRNA for carrying an arginine (or an expression cassette comprising such nucleic acid, or a vector (e.g., a viral vector) comprising such expression cassette) , the engineered tRNA comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises an A to G substitution at the 1 st nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 13 or SEQ ID NO: 16.
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1.
  • the nucleic acid encoding the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 13. In some embodiments, the nucleic acid encoding the engineered tRNA comprises a DNA sequence encoding the nucleotide sequence of SEQ ID NO: 16.
  • a nucleic acid encoding an engineered tRNA for carrying an arginine (or an expression cassette comprising such nucleic acid, or a vector (e.g., a viral vector) comprising such expression cassette) , the engineered tRNA comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises an A to G substitution at the 1 st nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1, and a U to C substitution at the 4th nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1, and a CCA sequence attached to the acceptor arm
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, or 2 nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16.
  • the nucleic acid encoding the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 8. In some embodiments, the nucleic acid encoding the engineered tRNA comprises a DNA sequence encoding the nucleotide sequence of SEQ ID NO: 8.
  • a nucleic acid encoding an engineered tRNA for carrying an arginine (or an expression cassette comprising such nucleic acid, or a vector (e.g., a viral vector) comprising such expression cassette) , the engineered tRNA comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises a U to A substitution at the 7th nucleotide 5’ to the anticodon, a U to C substitution at the 4th nucleotide 3’ to the anticodon, and an A to U substitution at the 7th nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1.
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16.
  • the nucleic acid encoding the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 61. In some embodiments, the nucleic acid encoding the engineered tRNA comprises a DNA sequence encoding the nucleotide sequence of SEQ ID NO: 61.
  • a nucleic acid encoding an engineered tRNA for carrying an arginine (or an expression cassette comprising such nucleic acid, or a vector (e.g., a viral vector) comprising such expression cassette) , the engineered tRNA comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises a G to U substitution at the 5th nucleotide 5’ to the anticodon, a U to C substitution at the 4th nucleotide 3’ to the anticodon, a C to A substitution at the 5th nucleotide 3’ to the anticodon, and an A to G substitution at the 7th nucleotide 3’ to the anticodon relative
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16.
  • the nucleic acid encoding the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 62. In some embodiments, the nucleic acid encoding the engineered tRNA comprises a DNA sequence encoding the nucleotide sequence of SEQ ID NO: 62.
  • a nucleic acid encoding an engineered tRNA for carrying an arginine (or an expression cassette comprising such nucleic acid, or a vector (e.g., a viral vector) comprising such expression cassette) , the engineered tRNA comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises a U to C substitution at the 7th nucleotide 5’ to the anticodon, a U to C substitution at the 4th nucleotide 3’ to the anticodon, and an A to G substitution at the 7th nucleotide 3’ to the anticodon relative to a tRNA having the sequence of SEQ ID NO: 1.
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16.
  • the nucleic acid encoding the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 63. In some embodiments, the nucleic acid encoding the engineered tRNA comprises a DNA sequence encoding the nucleotide sequence of SEQ ID NO: 63.
  • a nucleic acid encoding an engineered tRNA for carrying an arginine (or an expression cassette comprising such nucleic acid, or a vector (e.g., a viral vector) comprising such expression cassette) , the engineered tRNA comprising a T-arm, a D-arm, an anti-codon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises a G to C substitution at the 32nd nucleotide 5’ to the anticodon, a U to C substitution at the 30th nucleotide 5’ to the anticodon, a C to A substitution at the 28th nucleotide 5’ to the anticodon, an A to G substitution at the 8th nucleotide 5’ to the anticodon, an
  • the engineered tRNA comprises a nucleotide sequence that is at least about 85%(e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16.
  • the engineered tRNA contains no more than 12 (such as no more than about any of 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the nucleic acid encoding the engineered tRNA comprises a nucleotide sequence of SEQ ID NO: 64. In some embodiments, the nucleic acid encoding the engineered tRNA comprises a DNA sequence encoding the nucleotide sequence of SEQ ID NO: 64.
  • a nucleic acid encoding an engineered transfer RNA (tRNA) for carrying an arginine (or an expression cassette comprising such nucleic acid, or a vector (e.g., a viral vector) comprising such expression cassette) , the engineered tRNA comprising a T-arm, a D-arm, an anticodon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises one or more modifications relative to a tRNA having the sequence of SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16, and wherein the one or more modifications comprise: i) a G at the 1st nucleotide 3’ to the anticodon (corresponding to nucleic acid position 37, wherein the nucleic acid position corresponds to the
  • the engineered tRNA comprises a G at the 1st nucleotide 3’ to the anticodon (corresponding to nucleic acid position 37) . In some embodiments the engineered tRNA comprises a C at the 4th nucleotide 3’ to the anticodon (corresponding to nucleic acid position 40) . In some embodiments, the engineered tRNA comprises a CCA sequence attached to the acceptor arm at the 3’ end. Provided in some embodiments are nucleic acid molecules comprising RNA encoding any of the engineered tRNAs described herein.
  • the RNA comprises a sequence encoding a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 2-8, 61, 62, 63, and 64.
  • nucleic acid molecules comprising DNA encoding any of the engineered tRNAs described herein.
  • the DNA comprises a sequence encoding a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 2-8, 61, 62, 63, and 64.
  • engineered arginine transfer RNA Arg tRNA molecules that suppress the UGA premature stop codon to enable readthrough of the premature UGA stop codon in a template mRNA.
  • engineered tRNA suppressor molecules engineered suppressor tRNAs
  • suppressor tRNAs engineered suppressor tRNAs
  • up-tRNAs engineered tRNA suppressors
  • Arg-UGA sup-tRNAs engineered tRNA suppressors
  • the engineered tRNAs described herein have an anticodon sequence that base pairs with the UGA premature stop codon (also referred to herein as a PTC) , thus enabling the engineered tRNA, when charged with the arginine amino acid, to add the arginine to a growing polypeptide molecule, thus effecting readthrough of the premature stop codon.
  • UGA premature stop codon also referred to herein as a PTC
  • PTCs can be introduced into a coding sequence through, for example, a mutation.
  • a mutation can occur in a DNA molecule, an RNA molecule (e.g., tRNA, mRNA) , in a polypeptide or protein, or any combination thereof.
  • the reference sequence is obtained from a database, such as the NCBI Reference Sequence (RefSeq) Database.
  • the mutation comprises a substitution, a deletion, an insertion, an inversion, and/or a conversion in one or more nucleotides or one or more amino acids.
  • a mutation can include two or more sequence changes in different alleles, or two or more sequence changes in a single allele.
  • a mutation can include two different nucleotides at one position in one allele, such as a mosaic or a chimeric.
  • a mutation can be present in a malignant tissue.
  • a mutation can comprise a sequence variant, a sequence variation, a sequence alteration, and/or an allelic variant.
  • a mutation can result in the presence of a PTC.
  • a mutation changes an Arg-encoding codon to a UGA/TGA PTC.
  • Presence or an absence of a mutation can indicate an increased risk to develop a disease or condition.
  • a presence or an absence of a mutation can indicate a presence of a disease or condition.
  • a mutation can be present in a benign tissue. Absence of a mutation can but does not necessarily indicate that a tissue or sample can be benign.
  • the methods described herein can comprise identifying the presence of a mutation in a sample.
  • An engineered tRNA as described herein can recognize a premature UGA stop codon in an mRNA encoding a polypeptide and at least partially transform interpretation of a premature stop codon as a sense arginine codon, such as, for example by adding the correct (e.g., non-disease-causing) arginine amino acid to the growing peptide.
  • Such transformation also known as stop codon readthrough or PTC readthrough (also referred to synonymously herein as “read-through” ) , can produce a substantially full-length polypeptide at an efficiency of from about 1%to about 100%relative to a comparable polypeptide produced using a comparable mRNA that lacks the premature stop codon.
  • an efficiency can be at least about: 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%90%, 95%, or 99%. In some embodiments, an efficiency can be at least about: 1%to about 10%, 5%to about 20%, 10%to about 35%, 25%to about 50%, 40%to about 70%, 60%to about 80%, 75%to about 90%or about 85%to about 100%.
  • an efficiency of PTC readthrough can comprise an in vivo efficiency of PTC readthrough.
  • in vivo efficiency of PTC readthrough can be determined by at least partially treating a disease or condition.
  • in vivo efficiency of PTC readthrough can be measured by at least partially improving, for instance, the ability to produce a specific full-length protein, the absence and/or truncation of which is associated with a disease or disorder. Additional, non-limiting examples of possible in vivo measurements of efficiency of PTC readthrough include improving the ability to hear, improving the ability to see, improving motor ability, cognitive ability or any combination thereof.
  • an efficiency of PTC readthrough can comprise an in vitro efficiency of PTC readthrough, such as an in vitro efficiency of PTC readthrough as determined by, for example: (a) transfecting a first vector encoding an engineered tRNA and a second vector encoding a screening mRNA encoding a first marker protein, such as a luciferase protein or a green fluorescent protein into a first cell, such as a first human cell, where the screening mRNA encoding the first marker fluorescent protein can comprise a premature stop codon (this can be referred to herein as a (e.g., “broken” marker) ; (b) transfecting a third vector encoding a comparable screening mRNA encoding a second marker protein into a second cell, such as a second human cell, wherein the comparable screening mRNA does not comprise a premature stop codon; and (c) comparing an amount of a measurable output of the marker protein (e.g., fluorescence) from the
  • the engineered tRNA exhibits an increased PTC readthrough ability as compared to a tRNA having the sequence of SEQ ID NO: 1.
  • increased PTC readthrough ability is caused by increased tRNA stability.
  • increased PTC readthrough ability is caused by increased tRNA capability.
  • Increased capability of the engineered tRNA may be determined by, for instance, NanoLuc luciferase assay, RT-qPCR, Western Blot, protein pull down, or the mass spectrometry.
  • increased PTC readthrough ability is caused by increased tRNA abundance.
  • increased PTC readthrough ability is caused by switched tRNA chemical modifications.
  • increased PTC readthrough ability is caused by increased affinity for aminoacyl tRNA synthetase. In some embodiments, increased PTC readthrough ability is caused by increased tRNA affinity to the docking partner elongation factor EF-Tu/EF1A1. In some embodiments, increased PTC readthrough ability is caused by increased tRNA affinity to the ribosome. In some embodiments, increased PTC readthrough ability is caused by changes in other properties of the engineered tRNA as compared to a tRNA having the sequence of SEQ ID NO: 1. In some embodiments, increased PTC readthrough ability is caused by one or more (such as any of 2, 3, or 4) mechanisms discussed above.
  • the engineered tRNA exhibits an increased PTC readthrough ability as compared to a tRNA having the sequence of SEQ ID NO: 13.
  • increased PTC readthrough ability is caused by increased tRNA stability.
  • increased PTC readthrough ability is caused by increased tRNA capability.
  • Increased capability of the engineered tRNA may be determined by, for instance, NanoLuc luciferase assay, RT-qPCR, Western Blot, protein pull down, or the mass spectrometry.
  • increased PTC readthrough ability is caused by increased tRNA abundance.
  • increased PTC readthrough ability is caused by switched tRNA chemical modifications.
  • increased PTC readthrough ability is caused by increased affinity for aminoacyl tRNA synthetase. In some embodiments, increased PTC readthrough ability is caused by increased tRNA affinity to the docking partner elongation factor EF-Tu/EF1A1. In some embodiments, increased PTC readthrough ability is caused by increased tRNA affinity to the ribosome. In some embodiments, increased PTC readthrough ability is caused by changes in other properties of the engineered tRNA as compared to a tRNA having the sequence of SEQ ID NO: 13. In some embodiments, increased PTC readthrough ability is caused by one or more (such as any of 2, 3, or 4) mechanisms discussed above.
  • the engineered tRNA exhibits an increased PTC readthrough ability as compared to a tRNA having the sequence of SEQ ID NO: 16.
  • increased PTC readthrough ability is caused by increased tRNA stability.
  • increased PTC readthrough ability is caused by increased tRNA capability.
  • Increased capability of the engineered tRNA may be determined by, for instance, NanoLuc luciferase assay, RT-qPCR, Western Blot, protein pull down, or the mass spectrometry.
  • increased PTC readthrough ability is caused by increased tRNA abundance.
  • increased PTC readthrough ability is caused by switched tRNA chemical modifications.
  • increased PTC readthrough ability is caused by increased affinity for aminoacyl tRNA synthetase. In some embodiments, increased PTC readthrough ability is caused by increased tRNA affinity to the docking partner elongation factor EF-Tu/EF1A1. In some embodiments, increased PTC readthrough ability is caused by increased tRNA affinity to the ribosome. In some embodiments, increased PTC readthrough ability is caused by changes in other properties of the engineered tRNA as compared to a tRNA having the sequence of SEQ ID NO: 16. In some embodiments, increased PTC readthrough ability is caused by one or more (such as any of 2, 3, or 4) mechanisms discussed above.
  • the engineered tRNA exhibits an increased PTC read-through ability in vivo as compared to a tRNA having the sequence of SEQ ID NO: 1.
  • in vivo efficiency of PTC readthrough is measured as a percentage of substantially full-length polypeptides produced in vivo from an mRNA containing a premature UGA stop codon relative to the amount of a comparable polypeptide produced in vivo from a comparable mRNA that lacks a premature stop codon.
  • the engineered tRNA exhibits an increased PTC read-through ability in vivo as compared to a tRNA having the sequence of SEQ ID NO: 13.
  • in vivo efficiency of PTC readthrough is measured as a percentage of substantially full-length polypeptides produced in vivo from an mRNA containing a premature UGA stop codon relative to the amount of a comparable polypeptide produced in vivo from a comparable mRNA that lacks a premature stop codon.
  • the engineered tRNA exhibits an increased PTC read-through ability in vivo as compared to a tRNA having the sequence of SEQ ID NO: 16.
  • in vivo efficiency of PTC readthrough is measured as a percentage of substantially full-length polypeptides produced in vivo from an mRNA containing a premature UGA stop codon relative to the amount of a comparable polypeptide produced in vivo from a comparable mRNA that lacks a premature stop codon.
  • the engineered tRNA exhibits an increased PTC read-through ability in vitro as compared to a tRNA having the sequence of SEQ ID NO: 1.
  • in vitro PTC read-through ability is measured by in vitro efficiency of PTC readthrough.
  • in vitro efficiency of PTC readthrough is measured as a percentage of substantially full-length polypeptides produced in vitro from an mRNA containing a premature UGA stop codon relative to a comparable polypeptide produced in vitro from a comparable mRNA that lacks a premature stop codon.
  • the engineered tRNA exhibits an increased PTC read-through ability in vitro as compared to a tRNA having the sequence of SEQ ID NO: 13.
  • in vitro PTC read-through ability is measured by in vitro efficiency of PTC readthrough.
  • in vitro efficiency of PTC readthrough is measured as a percentage of substantially full-length polypeptides produced in vitro from an mRNA containing a premature UGA stop codon relative to a comparable polypeptide produced in vitro from a comparable mRNA that lacks a premature stop codon.
  • the engineered tRNA exhibits an increased PTC read-through ability in vitro as compared to a tRNA having the sequence of SEQ ID NO: 16.
  • in vitro PTC read-through ability is measured by in vitro efficiency of PTC readthrough.
  • in vitro efficiency of PTC readthrough is measured as a percentage of substantially full-length polypeptides produced in vitro from an mRNA containing a premature UGA stop codon relative to a comparable polypeptide produced in vitro from a comparable mRNA that lacks a premature stop codon.
  • An in vitro efficiency of PTC readthrough can be from about 1%to 100%, from about 10%to 100%, from about 20%to 100%, from about 30%to 100%, from about 40%to 100%, from about 50%to 100%, from about 60%to 100%, from about 70%to 100%, from about 75%to 100%. from about 80%to 100%, from about 85%to 100%, from about 90%to 100%, from about 95%to 100%, or from about 98%to 100%of the amount of a comparable polypeptide produced in vitro from a comparable mRNA that lacks a premature stop codon.
  • an in vitro efficiency of PTC readthrough can be from about 30%to 50%of the amount of a comparable polypeptide produced in vitro from a comparable mRNA that lacks a premature stop codon.
  • the engineered tRNAs disclosed herein are capable of premature stop codon readthrough, as disclosed herein.
  • the engineered tRNAs are capable of premature stop codon readthrough of a UGA/TGA stop codon mutation.
  • the premature stop codon is an Arg-to-UGA/TGA stop codon mutation.
  • the premature stop codon is of a UGA/TGA stop codon mutation from a codon encoding an amino acid other than arginine.
  • the protein resulting from the PTC readthrough has an identical sequence to a protein produced from a version of the coding sequence not containing a PTC.
  • the protein resulting from the PTC readthrough has a different sequence from a protein produced from a version of the coding sequence not containing a PTC.
  • determining the amount of full-length protein can be used to measure premature stop codon readthrough.
  • the Arg-to-UGA/TGA stop codon mutation is in a mammalian cell. In some embodiments, the Arg-to-UGA/TGA stop codon mutation is in a human cell. In some embodiments, the presence of the Arg-to-UGA/TGA stop codon mutation is associated with a disease or condition.
  • the engineered tRNA does not read through natural stop codons (that is, not premature; the termination signal that ends translation to result in a full-length functional protein/polypeptide, such that it is the last codon in a protein coding sequence (CDS) ) other than the premature UGA /TGA stop codon. In some embodiments, the engineered tRNA does read through stop codons other than the premature UGA/TGA stop codon. In some embodiments, the engineered tRNA reads through stop codons other than the premature UGA/TGA stop codon with a reduced efficiency compared to the efficiency with which the engineered tRNA reads through the UGA/TGA stop codon.
  • CDS protein coding sequence
  • the efficiency of read through of other stop codons is about 1%or less, about 10%or less, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or between about 90%and 100%compared to the efficiency with which the engineered tRNA reads through the UGA/TGA stop codon. In some embodiments, the efficiency of read through of other stop codons is less than about 10%. In some embodiments, the efficiency of read through of other stop codons is less than about 1%. In some embodiments, read through of other stop codons alters the function of the protein into which the engineered tRNA incorporates the amino acid. In some embodiments, read through of other stop codons does not alter the function of the protein into which the engineered tRNA incorporates the amino acid.
  • an engineered tRNA can be aminoacylated with a canonical amino acid. In some embodiments, the engineered tRNA provided herein is aminoacylated with arginine. In some embodiments, the engineered tRNA provided herein is aminoacylated with a canonical amino acid other than arginine. In some embodiments, an engineered tRNA can be aminoacylated with a non-canonical amino acid.
  • a non-canonical amino acid can comprise p-Acetylphenylalanine, p-Propargyloxyphenylalanine, p-Azidophenylalanine, O-methyltyrosine, p-Iodophenylalanine, 3-Iodotyrosine, Biphenylalanine, 2-Aminocaprylic acid, p-Benzoylphenylalanine, o-Nitrobenzylcysteine, o-Nitrobenzylserine, 4, 5-Dimethoxy-2-nitrobenzyl serine, o-Nitrobenzyllysine, Dansylalanine, Acetyllysine, Methylhistidine, 2-Aminononanoic acid, 2-Aminodecanoic acid, Cbz-lysine, Boc-lysine, or Allyloxycarbonyllysine.
  • the function of the protein into which the engineered tRNA incorporates the amino acid is not altered compared to a protein produced from a version of the mRNA not comprising a PTC. In some embodiments in which the engineered tRNA is aminoacylated with an amino acid other than arginine, the function of the protein into which the engineered tRNA incorporates the amino acid is altered compared to a protein produced from a version of the mRNA not comprising a PTC.
  • the engineered tRNAs described herein can exhibit improved suppression efficiency as compared with a corresponding parental tRNA, such as, for example, as compared with SEQ ID NO: 1.
  • SEQ ID NO: 1 corresponds to the RNA sequence of an Arg-TGA sup-tRNA known as R3-147, which is a derivative of the human tRNA Arg-TCT-1-1.
  • suppression efficiency can be more than or equal to about 30%, 50%, 70%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, or 400%higher than the suppression efficiency of SEQ ID NO: 1. In some embodiments, suppression efficiency can be more than about 300%higher than the suppression efficiency of SEQ ID NO: 1.
  • the engineered tRNA described herein can exhibit increased stability as compared with the stability of a corresponding parental tRNA, such as compared with the stability of SEQ ID NO: 1.
  • the stability is measured in vivo.
  • the stability is measured in vitro. Stability can be measured in different ways, for example, in terms of thermodynamic stability or shielding an engineered tRNA from degradation. Changing a base pair to G-C bond can at least provide a thermodynamic as well as a degradation shield, therefore stabilizing an engineered tRNA from degradation.
  • the engineered tRNA exhibits an increased stability in vivo as compared to a tRNA having the sequence of SEQ ID NO: 1.
  • the engineered tRNA exhibits an increased PTC readthrough capability in vivo or in vitro as compared to a tRNA having the sequence of SEQ ID NO: 1.
  • the PTC readthrough capability is determined by a NanoLuc luciferase assay, RT-qPCR, Western Blot, Immunoprecipitation, Mass Spectrometry, and/or Immunofluorescence.
  • the engineered tRNA stability increases by less than about 10%, by about 10%-20%, by about 20%-30%, by about 30%-40%, by about 40%-50%, by about 50%-60%, by about 60%-70%, by about 70%-80%, by about 80%-90%, by about 90%-100%, by about 100%-200%, by about 200%-300%, or by more than about 300%compared to a tRNA having the sequence of SEQ ID NO: 1.
  • the engineered tRNAs described herein can exhibit improved suppression efficiency as compared with a corresponding parental tRNA, such as, for example, as compared with SEQ ID NO: 13.
  • SEQ ID NO: 13 corresponds to the RNA sequence of an Arg-TGA sup-tRNA known as R3-5, which is a derivative of the human tRNA Arg-CCT-1-1.
  • suppression efficiency can be more than or equal to about 30%, 50%, 70%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, or 400%higher than the suppression efficiency of SEQ ID NO: 13. In some embodiments, suppression efficiency can be more than about 300%higher than the suppression efficiency of SEQ ID NO: 13.
  • the engineered tRNA described herein can exhibit increased stability as compared with the stability of a corresponding parental tRNA, such as compared with the stability of SEQ ID NO: 13.
  • the stability is measured in vivo.
  • the stability is measured in vitro. Stability can be measured in different ways, for example, in terms of thermodynamic stability or shielding an engineered tRNA from degradation. Changing a base pair to G-C bond can at least provide a thermodynamic as well as a degradation shield, therefore stabilizing an engineered tRNA from degradation.
  • the engineered tRNA exhibits an increased stability in vivo as compared to a tRNA having the sequence of SEQ ID NO: 13 In some embodiments, the engineered tRNA exhibits an increased PTC readthrough capability in vivo or in vitro as compared to a tRNA having the sequence of SEQ ID NO: 13.
  • the PTC readthrough capability is determined by a NanoLuc luciferase assay, RT-qPCR, Western Blot, Immunoprecipitation, Mass Spectrometry, and/or Immunofluorescence.
  • the engineered tRNA stability increases by less than about 10%, by about 10%-20%, by about 20%-30%, by about 30%-40%, by about 40%-50%, by about 50%-60%, by about 60%-70%, by about 70%-80%, by about 80%-90%, by about 90%-100%, by about 100%-200%, by about 200%-300%, or by more than about 300%compared to a tRNA having the sequence of SEQ ID NO: 13.
  • the engineered tRNAs described herein can exhibit improved suppression efficiency as compared with a corresponding parental tRNA, such as, for example, as compared with SEQ ID NO: 16.
  • SEQ ID NO: 16 corresponds to the RNA sequence of an Arg-TGA sup-tRNA known as R3-8, which is a derivative of the human tRNA Arg-CCT-4-1.
  • suppression efficiency can be more than or equal to about 30%, 50%, 70%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, or 400%higher than the suppression efficiency of SEQ ID NO: 16. In some embodiments, suppression efficiency can be more than about 300%higher than the suppression efficiency of SEQ ID NO: 16.
  • the engineered tRNA described herein can exhibit increased stability as compared with the stability of a corresponding parental tRNA, such as compared with the stability of SEQ ID NO: 16.
  • the stability is measured in vivo.
  • the stability is measured in vitro. Stability can be measured in different ways, for example, in terms of thermodynamic stability or shielding an engineered tRNA from degradation. Changing a base pair to G-C bond can at least provide a thermodynamic as well as a degradation shield, therefore stabilizing an engineered tRNA from degradation.
  • the engineered tRNA exhibits an increased stability in vivo as compared to a tRNA having the sequence of SEQ ID NO: 16.
  • the engineered tRNA exhibits an increased PTC readthrough capability in vivo or in vitro as compared to a tRNA having the sequence of SEQ ID NO: 16.
  • the PTC readthrough capability is determined by a NanoLuc luciferase assay, RT-qPCR, Western Blot, Immunoprecipitation, Mass Spectrometry, and/or Immunofluorescence.
  • the engineered tRNA stability increases by less than about 10%, by about 10%-20%, by about 20%-30%, by about 30%-40%, by about 40%-50%, by about 50%-60%, by about 60%-70%, by about 70%-80%, by about 80%-90%, by about 90%-100%, by about 100%-200%, by about 200%-300%, or by more than about 300%compared to a tRNA having the sequence of SEQ ID NO: 16.
  • the engineered tRNA restores less than 10%of the translation of the coding nucleic acid containing a premature UGA/TGA stop codon relative to a corresponding coding nucleic acid not containing the premature UGA/TGA stop codon. In some embodiments, the engineered tRNA restores at least 5%of the translation of the coding nucleic acid containing a premature UGA/TGA stop codon relative to a corresponding coding nucleic acid not containing the premature UGA/TGA stop codon.
  • the engineered tRNA restores at least 10%of the translation of the coding nucleic acid containing a premature UGA/TGA stop codon relative to a corresponding coding nucleic acid not containing the premature UGA/TGA stop codon. In some embodiments, the engineered tRNA restores between about 10-20%, 20%-30%, 30%-40%, 40%-50%, 50%-60%, 60%-70%, 70%-80%, 80%-90%, or 90%-100%of the translation of the coding nucleic acid containing a premature UGA/TGA stop codon relative to a corresponding coding nucleic acid not containing the premature UGA/TGA stop codon.
  • the engineered tRNA exhibits a different chemical modification pattern compared to a native tRNA. In some embodiments, presence of the engineered tRNA results in restoration of the function of a protein comprising a PTC. In some embodiments, an mRNA targeted by the engineered tRNA comprises one premature UGA stop codon. In some embodiments, an mRNA targeted by the engineered tRNA can comprise one, two, three, four, five, or more than five premature UGA stop codons. In some embodiments, different alleles of a given gene comprise one or more different TGA stop codons in different positions.
  • an individual has multiple different TGA -stop-codon-containing alleles of a gene, such as, for example, in the case of compound heterozygosity.
  • every copy of a gene present in an individual contains a TGA stop codon.
  • the presence of one or more UGA/TGA stop codons in an individual results in complete loss of function of the protein encoded by the gene.
  • the presence of one or more UGA/TGA stop codons in an individual results in partial loss of function of the protein encoded by the gene.
  • an engineered tRNA as described herein can produce readthrough of any or all of the one or more premature stop codons, thereby at least partially restoring a substantially full-length polypeptide.
  • at least partially restoring a substantially full-length polypeptide can comprise at least partially treating a disease or condition.
  • the engineered tRNA can reduce or prevent nonsense-mediated decay (NMD) of an mRNA containing one or more UGA PTCs.
  • NMD can be a quality control pathway that degrades PTC-containing mRNAs.
  • Some embodiments can include a method of inhibiting NMD comprising contacting a cell with an engineered tRNA described herein. In some embodiments, the contact can result in an increase in abundance of mRNAs containing UGA codons in the cell relative to a baseline measurement.
  • Some embodiments can include a method of inhibiting NMD of an mRNA containing one or more UGA PTCs in a subject, comprising administering to a subject an engineered tRNA.
  • the administration can result in a prevention or decrease of NMD-induced degradation of an mRNA containing one or more UGA PTCs in the subject.
  • the administration can result in an increase in abundance of an mRNA containing one or more UGA PTCs relative to a baseline measurement.
  • the increase in the target mRNA abundance can be measured by comparing abundance in a second sample taken from the subject to a baseline target mRNA measurement in a first sample taken from the subject.
  • the first and/or second samples can comprise a tissue or fluid sample described herein.
  • the engineered tRNA can decrease NMD-induced degradation of an mRNA containing one or more UGA PTCs by: 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%90%, 95%, 99%or 100%, or a range of any two of the aforementioned percentages.
  • the engineered tRNA can decrease NMD-induced degradation of an mRNA containing one or more UGA PTCs by at least about: 1%to about 10%, 5%to about 20%, 10%to about 35%, 25%to about 50%, 40%to about 70%, 60%to about 80%, 75%to about 90%or about 85%to about 100%.
  • the engineered tRNA is encoded by an expression cassette comprising a nucleic acid encoding the engineered tRNA.
  • the engineered tRNA is be introduced to cells using standard conventional genetic engineering techniques through use of vectors.
  • the engineered tRNA sequence is provided without a separate promoter, because of the internal promoter sequences of tRNA encoding sequences.
  • the engineered tRNA sequence is provided with a separate promoter.
  • Expression cassettes may include, for example, one or more promoter sequences operably linked to a nucleotide sequence of interest, which may further be operably linked to one or more termination sequences. Expression cassettes may also include, for example, sequences required for proper transcription of the nucleotide sequence. The coding region may code, for example, for an engineered tRNA. An expression cassette including a nucleotide sequence of interest may be chimeric. An expression cassette may contain naturally occurring sequences in a recombinant form useful for heterologous expression.
  • Expression of a nucleotide sequence in the expression cassette may be under the control of, for example, a constitutive promoter, a cell-type specific promoter, a temporal promoter, and/or a regulatable promoter that, for example, initiates transcription only when the host cell is exposed to a particular stimulus.
  • the promoter can also be specific to, for example, a particular tissue, organ, and/or or stage of development.
  • expression of the exogenous genetic material is driven by RNA polymerase III promoter, such as, for example, U6 promoter, H1 promoter and 7SK promoter.
  • expression of the exogenous genetic material is driven by a constitutive promoter, such as, for example, a promoter from any of the following “housekeeping” genes: hypoxanthine phosphoribosyl transferase (HPRT) , dihydrofolate reductase (DHFR) , adenosine deaminase, phosphoglycerate kinase (PGK) , pyruvate kinase, phosphoglycerate mutase, the actin promoter; or, for example, a viral promoters that functions constitutively in eukaryotic cells, such as, for example, the early and late promoters of SV40; the long terminal repeats (LTRs) of Moloney Leukemia Virus and other retroviruses; and the thymidine kinase promoter of Herpes Simplex Virus, among others. Coding sequences can be operably-linked to regulatory sequences in sense or antisense
  • the nucleotide expression cassette or nucleic acid of the invention is included within an appropriate gene transfer vehicle which is then used to transduce cells to express the suppressor tRNA.
  • the gene delivery vehicle can be any delivery vehicle known in the art, and can include, for example, naked DNA that is facilitated by a receptor, and/or lipid mediated transfection, and/or vectors.
  • vectors include but are not limited to eukaryotic vectors, prokaryotic vectors (such as, for example, bacterial vectors) , and viral vectors.
  • Exemplary viral vectors include retroviral vectors, adenoviral vectors, adeno-associated viral vectors, lentivirus vectors (human and other including porcine) , Herpes virus vectors, Epstein-Barr viral vectors, SV40 virus vectors, pox virus vectors, and pseudotyped viral vectors.
  • retroviral vectors are transduced.
  • viral vectors e.g., “transgene vectors”
  • the present invention encompasses transgene vectors that are suitable for use in the present invention that are linked to any gene of interest (or a “marker gene” or “reporter gene, ” used to indicate infection or expression of a gene) .
  • the engineered tRNA is encoded in a vector. In some embodiments, the engineered tRNA is encoded in a viral vector. In some embodiments, the viral vector is a retroviral, adeno-associated vector, or adenoviral vector. Exemplary retroviral vectors include, but are not limited to, spleen necrosis virus, Moloney Murine Leukemia Virus, and vectors derived from retroviruses such as avian leukosis virus, human immunodeficiency virus, Rous Sarcoma Virus, Harvey Sarcoma Virus, myeloproliferative sarcoma virus, and mammary tumor virus.
  • Vectors encoding the engineered tRNA molecules of the present disclosure are also provided herein.
  • the vectors are viral vectors in some cases.
  • various constructs for packaging engineered tRNA suppressor molecules in viral vectors including packaging of: one or multiple engineered tRNA suppressor payloads, markers such as GFP or mCherry, stuffer sequences, or any combination thereof.
  • Methods of delivering the engineered tRNA or vector encoding the engineered tRNA optionally packaged into a virus are also provided herein.
  • a vector can encode for an engineered tRNA or an engineered pre-tRNA.
  • a composition can comprise a vector.
  • a vector can comprise a plasmid or a viral vector.
  • a vector encoding the engineered tRNA or engineered pre-tRNA is administered to a subject.
  • Exemplary viral vectors can include an adenoviral vector, an adeno-associated viral (AAV) vector, a retroviral vector, a lentiviral vector, a portion of any of these, or any combination thereof.
  • the vector comprises DNA, such as double-stranded DNA or single-stranded DNA.
  • the vector comprises RNA.
  • the vector comprises a recombinant vector. In some embodiments, the vector is modified from a naturally occurring vector. In some embodiments, the RNA comprises a base modification. In some embodiments, the vector comprises at least a portion of a non-naturally occurring vector. Any vector can be utilized.
  • the vector comprises an AAV vector.
  • a vector can be modified to include a modified VP1 protein (such as an AAV vector modified to include a VP1 protein) .
  • the AAV is a recombinant AAV (rAAV) vector.
  • rAAVs can be composed of substantially similar capsid sequence and structure as found in wild-type AAVs (wtAAVs) , except that rAAVs encapsidate genomes that are substantially devoid of AAV protein-coding sequences and have therapeutic gene expression cassettes, such as engineered tRNA expression cassettes, designed in their place.
  • sequences of viral origin can be inverted terminal repeats (ITRs) , which can guide genome replication and packaging during vector production.
  • Suitable AAV vectors can be selected from any AAV serotype or combination of serotypes.
  • an AAV vector can be any one of: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV 10, AAV11, AAV12, or any combination thereof.
  • a vector is selected based on its natural tropism.
  • a vector serotype is selected based on its ability to cross the blood brain barrier, such as, for example AAV9 and/or AAV10.
  • an AAV vector is a chimera of at least two serotypes.
  • an AAV vector can be a chimera of serotypes AAV2 and AAV5.
  • a chimeric AAV vector can comprise rep and ITR sequences from AAV2 and a cap sequence from AAV5.
  • an AAV vector does not comprise a rep sequence.
  • a rep gene (such as, for example, from AAV2) is used in trans for AAV production.
  • an AAV vector can be self-complementary.
  • an AAV vector can be single-stranded AAV vector.
  • an AAV vector can be a self-complementary AAV vector.
  • an AAV vector can comprise an inverted terminal repeat (ITR) .
  • an AAV vector can comprise a self-complementary inverted terminal repeat (scITR) sequence.
  • rep, cap, and ITR sequences can be combined from any or all the of the AAV serotypes provided herein.
  • a suitable AAV vector can be further modified to encompass modifications such as in a capsid or rep protein. Such modifications can include deletions, insertions, mutations, and combinations thereof.
  • a modification to a vector can be made to reduce immunogenicity to allow for repeated dosing.
  • a serotype of a vector that can be utilized can be changed when repeated dosing can be performed to reduce and/or eliminate immunogenicity.
  • an AAV vector is from an AAV having a serotype comprising AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11 or AAV12, or a pseudotype comprising AAV-DJ, AAV-DJ/8, AAV-Rhl0, AAV-Rh74, AAV-retro, AAV-PHP. B, AAV8-PHP. eB, AAV-PHP. Sor AAV-2i8.
  • the AAV vector comprises a genome comprising a replication gene and inverted terminal repeats from a first AAV serotype and a capsid protein from a second AAV serotype.
  • the AAV vector comprises an AAV 2/2 vector, an AAV 2/5 vector, an AAV 2/6 vector, an AAV 2/7 vector, an AAV2/8 vector, or an AAV 2/9 vector.
  • the vector comprises from 2 to 6 copies of nucleic acids encoding an engineered tRNA per viral genome. In some embodiments, the vector comprises different engineered suppressor tRNAs with multiple copies per viral genome. In some embodiments, the vector comprises from 1 to 2, from 1 to 3, from 1 to 4, from 1 to 5, from 1 to 6, from 1 to 7, from 1 to 8, from 1 to 9, from 1 to 10, from 2 to 3, from 2 to 4, from 2 to 5, from 2 to 6, from 2 to 7, from 2 to 8, from 2 to 9, or from 2 to 10 copies per viral genome. In some embodiments, the vector comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 copies per viral genome. In some embodiments, the vector comprises from 1 to 5, from 1 to 10, from 1 to 15, from 1 to 20, from 1 to 25, from 1 to 30, from 1 to 35, from 1 to 40, from 1 to 45, or from 1 to 50 copies per viral genome.
  • a retroviral transgene vector is an expression vector bearing an expressible non-retroviral gene of interest and further includes at least one functional retroviral packaging signal.
  • the transgene vector is transcribed into RNA, and this RNA is packaged into an infectious viral particle, which then infects target cells.
  • the RNA in the viral particle is reverse transcribed into DNA, and the DNA is incorporated into the cell genome as a proviral element, thereby transmitting the gene of interest to the target cells.
  • an engineered tRNA or an expression cassette, vector, and/or nucleic acid encoding an engineered tRNA is present in a pharmaceutical composition.
  • the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. an excipient, and/or a diluent.
  • the pharmaceutically acceptable carrier is a liposome or a lipid nanoparticle.
  • liposomes are used to mediate delivery of the engineered tRNA.
  • lipid nanoparticles are used to mediate delivery of the engineered tRNA.
  • LNPs are used to deliver synthetic RNA.
  • compositions described herein comprising the engineered tRNA molecule (s) or the vector (s) encoding the engineered tRNA molecule (s) can employ an AAV vector for delivery to a subject.
  • AAV vector delivery can achieve long-term benefit with single dose and can provide opportunity for multiplexed targeting.
  • an engineered tRNA, a vector encoding the engineered tRNA, or both can be present in a delivery system.
  • the delivery system comprises a viral particle, a liposome, a nanoparticle, an exosome, an extracellular vesicle, a nanomesh, a charged polymer, an uncharged polymer, a surfactant, a penetrating enhancer, a gene transfer agent, a phospholipid, a micelle, a synthetic vector, a macromolecule, a dendrimer, a biopolymer, or any combination thereof.
  • an engineered tRNA or a vector encoding the engineered tRNA can be present in a viral particle, a liposome, a nanoparticle, an exosome, an extracellular vesicle, a nanomesh, or any combination thereof.
  • the vector is inside a polypeptide coat.
  • a composition comprises an excipient.
  • An excipient can be, for example, added to a stem cell or co-isolated with the stem cell from a source.
  • An excipient can comprise a cryo-preservative, such as DMSO, glycerol, polyvinylpyrrolidone (PVP) , or any combination thereof.
  • An excipient can comprise a cryo-preservative, such as a sucrose, a trehalose, a starch, a salt of any of these, a derivative of any of these, or any combination thereof.
  • An excipient can comprise a pH agent (for example, to minimize oxidation or reduction of a component of the composition) , a stabilizing agent (for example, to prevent modification or degradation of a component of the composition) , a buffering agent (for example, to enhance temperature stability) , a solubilizing agent (for example, to increase protein solubility) , or any combination thereof.
  • An excipient can comprise a surfactant, a sugar, an amino acid, an antioxidant, a salt, a non-ionic surfactant, a solubilizer, a triglyceride, an alcohol, or any combination thereof.
  • An excipient can comprise sodium carbonate, acetate, citrate, phosphate, poly-ethylene glycol (PEG) , human serum albumin (HSA) , sorbitol, sucrose, trehalose, sodium phosphate, disodium phosphate, mannitol, polysorbate 20, histidine, citrate, albumin, sodium hydroxide, glycine, sodium citrate, arginine, sodium acetate, HC1, disodium edetate, lecithin, glycerine, xanthan rubber, soy isoflavones, polysorbate 80, ethyl alcohol, water, teprenone, or any combination thereof.
  • An excipient can be an excipient described in the Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (1986) .
  • a composition described herein can comprise a naturally-occurring or non-naturally-occurring carrier.
  • the carrier is inert (for example, a detectable agent or label) .
  • the carrier is active, such as an adjuvant, diluent, binder, stabilizer, buffers, salts, lipophilic solvents, preservative, adjuvant or the like.
  • a carrier comprises a pharmaceutically acceptable carrier.
  • a carrier includes pharmaceutical excipients and additives proteins, peptides, amino acids, lipids, and carbohydrates (e.g., sugars, including monosaccharides, di-, tri-, tetra-oligosaccharides, and oligosaccharides; derivatized sugars such as alditols, aldonic acids, esterified sugars and the like; and polysaccharides or sugar polymers) , which can be present singly or in combination, comprising alone or in combination 1-99.99%by weight or volume.
  • Exemplary protein excipients include serum albumins such as human serum albumin (HSA) , recombinant human albumin (rHA) , gelatin, casein, and the like.
  • Representative amino acid components, antibody components, or both, which can also function in a buffering capacity include alanine, arginine, glycine, betaine, histidine, glutamic acid, aspartic acid, cysteine, lysine, leucine, isoleucine, valine, methionine, phenylalanine, aspartame, and the like.
  • carbohydrate excipients such as, for example, monosaccharides such as fructose, maltose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides, such as lactose, sucrose, trehalose, cellobiose, and the like; polysaccharides, such as raffinose, melezitose, maltodextrins, dextrans, starches, and the like; and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitol sorbitol (glucitol) , and myoinositol.
  • monosaccharides such as fructose, maltose, galactose, glucose, D-mannose, sorbose, and the like
  • disaccharides such as lactose, sucrose, trehalose, cellobiose,
  • compositions provided herein can comprise a diluent, such as, for example, water, glycerol, methanol, ethanol, and other similar biocompatible diluents.
  • a diluent such as, for example, water, glycerol, methanol, ethanol, and other similar biocompatible diluents.
  • the diluent is an aqueous acid such as acetic acid, citric acid, maleic acid, hydrochloric acid, phosphoric acid, nitric acid, sulfuric acid, or similar.
  • the diluent is an alkaline metal carbonate such as calcium carbonate; an alkaline metal phosphate such as calcium phosphate; an alkaline metal sulphate such as calcium sulphate; a cellulose derivative such as cellulose, microcrystalline cellulose, or cellulose acetate; magnesium oxide, dextrin, fructose, dextrose, glyceryl palmitostearate, lactitol, choline, lactose, maltose, mannitol, simethicone, sorbitol, starch, pregelatinized starch, talc, xylitol and/or anhydrates, hydrates and/or pharmaceutically acceptable derivatives thereof or combinations thereof.
  • an alkaline metal carbonate such as calcium carbonate
  • an alkaline metal phosphate such as calcium phosphate
  • an alkaline metal sulphate such as calcium sulphate
  • a cellulose derivative such as cellulose, microcrystalline cellulose, or cellulose a
  • the nucleic acid encoding the engineered tRNA is encoded by a nucleic acid that can be delivered to a host cell via viral or non-viral based methods.
  • Methods of non-viral delivery of nucleic acids include lipofection, nucleofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid: nucleic acid conjugates, electroporation, nanoparticles, exosomes, microvesicles, or gene-gun, naked DNA and artificial virions. See, for example, Sambrook et al. (2012, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York) .
  • RNA or DNA viral based systems for the delivery of nucleic acids has high efficiency in targeting a virus to specific cells and trafficking the viral payload to the cellular nuclei.
  • the method comprises introducing a viral vector (such as an AAV or a lentiviral vector) encoding the nucleic acid encoding the engineered tRNA to the host cell.
  • a viral vector such as an AAV or a lentiviral vector
  • the vector is a recombinant adeno-associated virus (rAAV) vector.
  • the construct is flanked by one or more AAV inverted terminal repeat (ITR) sequences.
  • ITR inverted terminal repeat
  • the construct is flanked by two AAV ITRs.
  • the AAV ITRs are AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, a goat AAV, bovine AAV, or mouse AAV serotype ITRs.
  • the AAV ITRs are AAV2 ITRs.
  • the vector further comprises a stuffer nucleic acid.
  • the stuffer nucleic acid is located upstream or downstream of the nucleic acid encoding the tRNA.
  • the vector is a self-complementary rAAV vector.
  • the vector comprises first nucleic acid sequence encoding the nucleic acid encoding the engineered tRNA and a second nucleic acid sequence encoding a complement of the nucleic acid encoding the engineered tRNA, wherein the first nucleic acid sequence can form intrastrand base pairs with the second nucleic acid sequence along most or all of its length.
  • the first nucleic acid sequence and the second nucleic acid sequence are linked by a mutated AAV ITR, wherein the mutated AAV ITR comprises a deletion of the D region and comprises a mutation of the terminal resolution sequence.
  • the vector is encapsidated in a rAAV particle.
  • the AAV viral particle comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV2/2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV2 V708K, AAV2-HBKO, AAVDJ8, AAV-PHP. B, AAV-PHP. eB, AAV-BR1, AAVHSC15, AAVHSC17, goat AAV, AAV1/AAV2 chimeric, bovine AAV, mouse AAV, or rAAV2/HboV1 serotype capsid.
  • the method comprises introducing a plasmid encoding the nucleic acid encoding the engineered tRNA to the host cell. In some embodiments, the method comprises electroporation of the nucleic acid encoding the engineered tRNA (e.g., synthetic nucleic acid encoding the engineered tRNA) into the host cell. In some embodiments, the method comprises transfection of the nucleic acid encoding the engineered tRNA into the host cell.
  • the method comprises electroporation of the nucleic acid encoding the engineered tRNA (e.g., synthetic nucleic acid encoding the engineered tRNA) into the host cell.
  • the method comprises transfection of the nucleic acid encoding the engineered tRNA into the host cell.
  • the engineered tRNA is delivered to a subject. In some embodiments, the engineered tRNA is delivered to a cell. In some embodiments, the cell is in a subject. In some embodiments, the subject and/or cell is eukaryotic. In some embodiments, the subject and/or cell is mammalian. In some embodiments, the subject and/or cell is human.
  • the present application further provides methods of suppressing PTC by using the engineered tRNAs provided herein.
  • the engineered tRNA (or nucleic acid encoding the engineered tRNA) is used to treat a disease associated with a premature UGA/TGA codon.
  • a method of treating a disease associated with a premature UGA/TGA stop codon in an individual comprises administering to the individual an effective amount of a pharmaceutical composition comprising an engineered tRNA, an expression cassette comprising a nucleic acid encoding an engineered tRNA, and/or a vector comprising an expression cassette comprising a nucleic acid encoding an engineered tRNA, and further comprising a pharmaceutically acceptable carrier.
  • the effective amount can depend on, for example, the type and severity of the condition at issue and the characteristics of the individual subject, such as general health, age, sex, body weight, and/or tolerance to pharmaceutical compositions.
  • an effective amount can be an amount that can be required to at least partially treat a patient with a disease associated with the presence of a PTC.
  • the effective amount depends on the size and nature of the particular application and/or on the nature and/or sensitivity of the in vitro target and the methods in use.
  • the effective amount comprises one or more administrations of a composition.
  • a method of restoring translation of a coding nucleic acid containing a premature UGA/TGA stop codon in (or a method of reading through a nucleic acid containing a premature UGA/TGA stop codon) a host cell comprising introducing to the host cell an engineered tRNA for carrying an arginine (or an expression cassette comprising a nucleic acid encoding the engineered tRNA, or a vector comprising an expression cassette comprising a nucleic acid encoding the engineered tRNA) , wherein the engineered tRNA comprises a T-arm, a D-arm, an anticodon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises one or more modifications relative to a tRNA having the sequence
  • the engineered tRNA has a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1. In some embodiments, the method is carried out ex vivo. In some embodiments, the method of carried out in vivo.
  • a method of restoring translation of a coding nucleic acid containing a premature UGA/TGA stop codon in (or a method of reading through a nucleic acid containing a premature UGA/TGA stop codon) a host cell comprising introducing to the host cell an engineered tRNA for carrying an arginine (or an expression cassette comprising a nucleic acid encoding the engineered tRNA, or a vector comprising an expression cassette comprising a nucleic acid encoding the engineered tRNA) , wherein the engineered tRNA comprises a T-arm, a D-arm, an anticodon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises one or more modifications relative to a tRNA having the sequence
  • the engineered tRNA has a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 13. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 13. In some embodiments, the method is carried out ex vivo. In some embodiments, the method of carried out in vivo.
  • a method of restoring translation of a coding nucleic acid containing a premature UGA/TGA stop codon in (or a method of reading through a nucleic acid containing a premature UGA/TGA stop codon) a host cell comprising introducing to the host cell an engineered tRNA for carrying an arginine (or an expression cassette comprising a nucleic acid encoding the engineered tRNA, or a vector comprising an expression cassette comprising a nucleic acid encoding the engineered tRNA) , wherein the engineered tRNA comprises a T-arm, a D-arm, an anticodon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises one or more modifications relative to a tRNA having the sequence
  • the engineered tRNA has a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 16. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 16. In some embodiments, the method is carried out ex vivo. In some embodiments, the method of carried out in vivo.
  • the method of suppressing PTC by using the engineered tRNAs provided herein can comprise delivery of a mixture of multiple types of engineered tRNAs and/or nucleic acids encoding multiple types of engineered tRNAs, such as simultaneous or non-simultaneous delivery of 2 or more, 3 or more, 4 or more, or 5 or more different engineered tRNAs, and/or simultaneous or non-simultaneous delivery of 2 or more, 3 or more, 4 or more, or 5 or more different nucleic acids, each encoding a different engineered tRNA, and/or delivery of only 1 nucleic acid that encodes multiple different engineered tRNAs.
  • the different engineered tRNAs suppress the same PTC (e.g., UGA) .
  • each of the different engineered tRNAs suppresses a different PTC (e.g., one or more engineered tRNAs suppress the UGA PTC, and one or more different engineered tRNAs suppress a different PTC) .
  • at least one of the different engineered tRNAs is an engineered Arg-UGA engineered tRNA described herein.
  • all of the different engineered tRNAs are different engineered Arg-UGA engineered tRNA described herein.
  • read through it is meant that the engineered tRNA affects translation of a PTC-containing mRNA, resulting in the incorporation of an arginine at the PTC in the nascent growing polypeptide chain, rather than termination of translation and generation of a truncated protein, which would otherwise occur.
  • Methods for determining whether an engineered tRNA result in read through include, for example, western blot analysis, immunohistochemistry, flow cytometry, mass spectrometry, as well as cell-based reporter assays such as those described in the Examples section.
  • improvement in one or more clinical parameters allows for determining whether a PTC correction agent is effectively increasing levels of full-length protein.
  • even modest or slight increases in the amount of full-length protein are beneficial in alleviating some disease states.
  • the lysosomal storage disease mucopolysaccharidosis type I-Hurler (MPS I-H, caused by nonsense mutation resulting in decreased levels of iduronidase encoded by the IDUA gene) , has a low threshold for correction, since ⁇ 1%of wild-type iduronidase function can significantly moderate the clinical phenotype (Ashton et al., Am. J. Hum. Genet. 1992, 50: 787-794, Bunge et al., Biochim. Biophys. Acta. 1998, 1407: 249-256) .
  • increasing the amount of full-length protein, in some aspects, to reach 1%of wild-type levels is beneficial in treating some diseases caused by nonsense mutations.
  • the method results in an increase of at least 5%, such as 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or a 100%increase, in the amount of full length protein produced, for example as compared to wild type levels (e.g., levels of expression of the wild-type protein wherein the gene/mRNA does not contain a nonsense mutation) .
  • wild type levels e.g., levels of expression of the wild-type protein wherein the gene/mRNA does not contain a nonsense mutation
  • increased levels of the full-length beta chains of hemoglobin leads to improved or ameliorated disease states, such as decreased or no anemia, decreased tiredness, decreased breathlessness, and increased exercise tolerance.
  • Methods for monitoring improvement in the ⁇ -thalassemia disease state include, for example, pulse oximetry, hemoglobin electrophoresis; serum transferrin, ferritin, Fe binding capacity analysis; urine urobilin &urobilinogen assays; peripheral blood smear test; hematocrit analysis; and serum bilirubin analysis.
  • the host cell is a eukaryotic cell.
  • the host cell is a mammalian cell.
  • the host cell is a human cell.
  • the host cell is a murine cell.
  • the host cell is a plant cell or a fungal cell.
  • the host cell is a diseased cell.
  • the host cell comprises one or more mutations, such as a nonsense mutation.
  • the host cell is a cell line, such as Neuro-2a, HEK293T, HT29, NCI-60, MCF-7, HL-60, A549, HepG2, RD, SF268, SW13, LHCN differentiated, LHCN undifferentiated, Saos-2, CHO, or HeLa cells.
  • the host cell is a primary cell, such as fibroblast, epithelial, or immune cell.
  • the host cell is a T cell.
  • the host cell is a post-mitosis cell.
  • the host cell is a cell of the central nervous system (CNS) , such as a brain cell, e.g., a cerebellum cell.
  • the host cell is an immortalized PTC containing cell.
  • the host cell is a PTC-containing stem cell or IPS cell.
  • the host cell is from a PTC-containing stem cell-or IPS cell-differentiated cells or organoids.
  • the host cell is a neuron, a photoreceptor cell (e.g. a S cone cell, a L cone cell, a M cone cell, a rod cell) , a retinal pigment epithelium cell, a glia cell (e.g. an astrocyte, an oligodendrocyte, a microglia) , a muscle cell (e.g. a myoblast, a myotube) , a hepatocyte, or a lung epithelial cell.
  • a cell can be a horizontal cell, a ganglion cell, or a bipolar cell.
  • the host cell is in an individual, such as a human individual. In some embodiments, the host cell is an ex vivo cell population.
  • the coding nucleic acid containing a premature UGA/TGA stop codon is an mRNA.
  • the premature UGA/TGA stop codon (also referred to as “PTC” ) results from a nonsense mutation, such as a disease-causing mutation (such as a disease-causing mutation described herein) .
  • the disease can be caused by the rapid turnover (e.g., by NMD) of the mRNA, a lack or reduced production of functional protein due to a truncated protein product, insufficient levels of a truncated protein product having normal or partial function, or combinations thereof.
  • the PTC is a PTC resulting from abnormal or inefficient biogenesis of mRNAs.
  • the PTC is not the result of a mutation, such as, for example as the result of one or more errors introduced during transcription of non-mutated DNA.
  • mutations resulting in a PTC have important consequences on gene expression, such as in the context of disease.
  • a PTC will terminate mRNA translation prior to completion of a full-length polypeptide, leading to production of truncated proteins that are often partially functional, nonfunctional, unstable, and/or have detrimental function.
  • PTC-containing mRNAs are also frequently unstable because the mRNAs are degraded by NMD, resulting in a severe reduction in steady-state mRNA levels.
  • the combination of these PTC-induced events reduce the level of functional protein produced to such an extent that a severe disease state results.
  • the PTC-containing mRNA described herein can be transcribed from any gene of interest.
  • the PTC-containing mRNA is transcribed from a gene selected from the group consisting of IDUA, CFTR, DMD, HBB, and MECP2.
  • the PTC-containing mRNA is transcribed from IDUA. Additional nonsense mutations can be found in, for example, the Human Gene Mutation Database (HGMD) and the ClinVar (Landrum, M.J., et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res . 2018 Jan 4. PubMed PMID: 29165669) .
  • a composition described herein e.g., a composition comprising an engineered tRNA or a nucleic acid encoding the engineered tRNA
  • a composition as described herein can be administered prophylactically to prevent an incidence of a disease or condition. Prevention can at least partially reduce an appearance, onset, or incidence of one or more symptoms of a disease or condition.
  • a method of treating a disease associated with a premature UGA/TGA stop codon in an individual comprising: administering to the individual an effective amount of a pharmaceutical composition comprising an engineered transfer RNA (tRNA) for carrying an arginine comprising a T-arm, a D-arm, an anticodon arm, a variable region, and an acceptor arm (or an expression cassette comprising a nucleic acid encoding the engineered tRNA, or a vector comprising an expression cassette comprising a nucleic acid encoding the engineered tRNA) , wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises one or more modifications relative to a tRNA having the sequence of SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16, and wherein the one or more modifications comprise: i
  • the engineered tRNA has a nucleotide sequence that is at least about 85% (e.g., at least about any of 87%, 90%, 92%, or 95%) identical to SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16. In some embodiments, the engineered tRNA contains no more than 5 (such as no more than about any of 4, 3, 2, or 1) nucleotide substitutions relative to SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16) .
  • compositions for use in treating a disease associated with a premature UGA/TGA stop codon in an individual.
  • a composition described herein can be administered to treat a disease or condition as described herein.
  • a composition as described herein can be administered after onset or diagnosis of a disease to prevent continuing or worsening of the disease or condition, and/or to reduce the severity of symptoms, such as by at least partially reduce an appearance, onset, or incidence of one or more symptoms of a disease or condition. Any disease associated with a nonsense allele may be treated using the compositions and methods provided herein.
  • compositions and methods provided herein include, but are not limited to, Shwachman-Diamond syndrome, Alport syndrome, Stargardt disease, Usher syndrome, ataxia telangiectasia, hemophilia A and B, Hailey-Hailey disease, Ullrich disease, methylmalonic acidemia, carnitine palmitoyltransferase 1A deficiency, peroxisome biogenesis disorders, limb girdle muscular dystrophy, Schmid metaphyseal chondrodysplasia, Sandhoff disease, Marfan syndrome, anemia, epidermolysis bullosa simplex, Tay-Sachs disease, triose phosphate isomerase deficiency, Alzheimer's disease, long-QT syndrome, insulin resistance, maple syrup urine disease, hereditary fructose intolerance, X-linked severe combined immunodeficiency, infantile neuronal ceroid lipofuscinosis, cystinosis, X-linked n
  • Any suitable subject can be administered a composition as described herein or treated by a method as described herein.
  • mammals include humans, non-human primates (e.g., apes, gibbons, chimpanzees, orangutans, monkeys, macaques, and the like) , domestic animals (e.g., dogs and cats) , farm animals (e.g., horses, cows, goats, sheep, pigs) , and experimental animals (e.g., mouse, rat, rabbit, guinea pig) .
  • the subject is a human.
  • the subject can be any age or at any stage of development (e.g., an adult, teen, child, infant, or a mammal in utero) .
  • a human can be an embryo, a fetus, a child, or an adult.
  • a human can be from about: 1 day to about 7 days old, 1 week to about 5 weeks old, 1 month to about 12 months old, 1 year to about 10 years old, 6 months to about 15 years old, 5 years to about 25 years old, 20 years to about 50 years old, 40 years to about 80 years old, 75 years to about 100 years old, or about 90 years to about 130 years old.
  • a mammal can be male or female. In some embodiments, the subject is male.
  • the subject is female.
  • a subject can be a pregnant subject, such as a pregnant human at an age appropriate for reproduction.
  • the patient can about 20 years of age.
  • the patient can 10-30 years of age.
  • a subject has or is suspected of having a disease or condition.
  • a subject has or is suspected of having one or more PTCs associated with a disease or condition.
  • the subject has a disease or condition caused by one or more PTCs.
  • the subject has one or more Arg-to-stop PTCs.
  • a subject has received a diagnosis of a disease or a condition. In some embodiments, a subject has not received a diagnosis of a disease or condition.
  • a diagnosis can include a blood test, a clinical diagnosis based on one or more symptoms, or any combination thereof.
  • a diagnostic (such as a blood test) can confirm a presence or an absence of a mutation (e.g., a UGA PTC) in an mRNA encoding a polypeptide.
  • a diagnostic test can comprise sequencing (e.g. Sanger sequencing, Illumina sequencing, or sequencing by synthesis) a biological sample from a subject.
  • a presence or an absence of a mutation in a portion of an mRNA can include a plurality of mutations (such as from about 1 to about 200 mutations) .
  • a clinical diagnosis can be based on one or more symptoms, such as, for example, loss of speech, loss of purposeful use of hands, involuntary hand movements, loss of mobility, gait disturbances, loss of muscle tone, seizures, scoliosis, sleep disturbances, slowed growth rate, difficulty breathing, loss of hearing, muffing of speech and sounds, difficulty understanding words, trouble hearing consonants, a loss of vision, a restricted vision field, a cloudiness of vision, a blurred vision, eye discomfort, a cough, a cough with phlegm, fatty stools, infertility, weight loss, salty skin, or any combination thereof.
  • a pregnant female subject is administered a composition described herein at one or more stages of pregnancy.
  • a female subject is administered the composition during a prenatal period.
  • an embryo or a fetus can be administered a composition as described herein in the womb.
  • an embryo can be administered a composition as described herein in an in vitro setting.
  • a disease or condition can comprise, for example, Rett syndrome, autism, West syndrome, Lennox-Gastaut syndrome, epileptic encephalopathy (EEP) , Pitt-Hopkins syndrome, comprise cystic fibrosis, deafness (e.g. autosomal dominant 17 deafness, autosomal dominant 13 deafness, autosomal dominant 11 deafness) retinitis pigmentosa, Tay-Sachs, Parkinson’s, Cystic Fibrosis, Usher syndrome, Wolman disease, a liver disease (Alpha-1 antitrypsin (AAT) deficiency) , a neurodegenerative disease, a muscular disorder, a metabolic disorder, an ocular disorder (e.g.
  • an ocular disease a cancer, albinism, Alzheimer’s disease, Amyotrophic lateral sclerosis, Asthma, ⁇ -thalassemia, Cadasil syndrome, Charcot-Marie-Tooth disease, Chronic Obstructive Pulmonary Disease (COPD) , dementia, Distal Spinal Muscular Atrophy (DSMA) , Dystrophic Epidermolysis bullosa, Epidermylosis bullosa, Fabry disease, Factor V Leiden associated disorders, Familial Adenomatous, Polyposis, Galactosemia, Gaucher's Disease, Glucose-6-phosphate dehydrogenase, Hemophilia, Hereditary Hematochromatosis, Hunter Syndrome, Huntington's disease, Hurler Syndrome, Inflammatory Bowel Disease (IBD) , Inherited polyagglutination syndrome, Leber congenital amaurosis, Lesch-Nyhan syndrome, Lynch syndrome, Marfan syndrome, Mucopolysaccharidosis
  • a disease or condition can comprise a muscular dystrophy, such as, for example, myotonic, Duchenne, Becker, Limb-girdle, facioscapulohumeral, congenital, oculopharyngeal, distal, Emery-Dreifuss, or any combination thereof.
  • a disease or condition can comprise pain, such as chronic pain. Pain can include neuropathic pain, nociceptive pain, or a combination thereof. Nociceptive pain can include visceral pain, somatic pain, or a combination thereof.
  • treatment comprises administration to a subject one or more compositions as described herein.
  • treatment comprises administration of a co-therapy to a subject, such as, for example, co-therapy comprising the engineered tRNA alongside, for example, a cancer treatment (e.g. radiotherapy, chemotherapy, CAR-T therapy, immunotherapy, hormone therapy, cryoablation) , surgery, antibiotics, antivirals, or any combination thereof.
  • a cancer treatment e.g. radiotherapy, chemotherapy, CAR-T therapy, immunotherapy, hormone therapy, cryoablation
  • surgery antibiotics, antivirals, or any combination thereof.
  • co-therapy comprises a mucus thinner, cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies, a lung transplant, bronchodilator, airway clearance, an anti inflammatory medication, nebulizer treatment, an oral pancreatic enzyme, a stool softener, elexacaftor, ivacaftor and tezacaftor, lumacaftor, or any combination thereof.
  • CFTR cystic fibrosis transmembrane conductance regulator
  • a co-therapy comprises physical therapy, hydrotherapy, occupational therapy, speech-language therapy, feeding assistance, an antiepileptic drug, an antireflux drug, levocarnitine, steroid therapy, nonsteroidal anti-inflammatory drug (NSAID) , vision aids (e.g. glasses, and/or corrective eye surgery) , hearing treatment (e.g., hearing aids) , or any combination thereof.
  • co-therapy comprises an RNA or DNA editing technology.
  • treatment includes curing a disease or condition.
  • treatment includes substantially reducing one or more symptoms of a disease or condition.
  • administration of the engineered tRNA results in a reduction in at least one symptom associated with a genetic disease.
  • the amount and form of tRNA or nucleic acid encoding tRNA administered will vary depending on various factors such as, for example, the composition chosen, the particular disease, weight, physical condition, and age of the subject, and whether prevention or treatment is the goal.
  • the reduction in at least one symptom occurs with less than about 1%, less than about 5%, less than about 10%, less than about 20%, less than about 30%, less than about 40%, less than about 50%, less than about 60%, less than about 70%, less than about 80%, less than about 90%, or less than about 100%of restoration of translation of a mRNA comprising a PTC.
  • the reduction in at least one symptom occurs with less than about 10%of restoration of translation of a mRNA comprising a PTC.
  • restoration of translation is measured as the amount of full-length protein produced in a sample comprising an mRNA comprising the PTC relative to a comparative sample comprising a comparative mRNA encoding the same protein but not comprising the PTC.
  • the endogenous DNA sequences encoding the endogenous tRNAs of the subject do not comprise a CCA sequence at the 3’ end of the sequence encoding the acceptor arm.
  • a CCA sequence is attached post-transcriptionally to the acceptor arm at the 3’ end of endogenous tRNAs.
  • compositions disclosed herein are in unit dose forms. In some embodiments, compositions disclosed herein are in multiple-dose forms.
  • Unit dose forms can refer to physically discrete units suitable for administration to human or non-human subjects (e.g., animals) . In some embodiments, unit dose forms are packaged individually.
  • unit dose forms can comprise a mixture of multiple types of engineered tRNAs. For example, a single unit dose can comprise a mixture of 2 or more, 3 or more, 4 or more, or 5 or more different engineered tRNAs. In some embodiments, the different engineered tRNAs suppress the same PTC (e.g., UGA) .
  • each of the different engineered tRNAs suppresses a different PTC (e.g., one or more engineered tRNAs suppress the UGA PTC, and one or more different engineered tRNAs suppress a different PTC) .
  • at least one of the different engineered tRNAs is an engineered Arg-UGA engineered tRNA described herein.
  • all of the different engineered tRNAs are different engineered Arg-UGA engineered tRNA described herein.
  • Each unit dose can contain a predetermined quantity of an active ingredient (s) that can be sufficient to produce the desired therapeutic effect in association with pharmaceutical carriers, diluents, excipients, or any combination thereof.
  • active ingredient examples include ampoules, syringes, and individually packaged tablets and capsules.
  • a unit dose form is packaged in a disposable syringe. In some embodiments, a unit dose form is administered in fractions or multiples.
  • a multiple-dose form can be a plurality of identical unit dose forms packaged in a single container, which can be administered in segregated a unit dose form. Examples of a multiple-dose form can include vials, bottles of tablets or capsules, or bottles of pints or gallons.
  • a multiple-dose form comprises multiple doses of the same pharmaceutically active agents. In some embodiments, a multiple-dose form comprises doses of different pharmaceutically active agents.
  • a composition described herein is administered to enable the delivery of an engineered tRNA or a vector encoding an engineered tRNA to a desired site of biological action.
  • administration includes, for example, oral administration, topical administration, intravenous administration, inhalation administration, or any combination thereof.
  • delivery includes injection, catheterization, gastrostomy tube administration, intraosseous administration, ocular administration, intracerebroventricular administration, otic administration, transdermal administration, oral administration, rectal administration, nasal administration, intravaginal administration, intracavernous administration, transurethral administration, sublingual administration, intracranial injection, intracranial injection into the parenchyma, intracisternal magna (ICM) , intra-cerebroventricular (ICV) or a combination thereof.
  • ICM intracisternal magna
  • IMV intra-cerebroventricular
  • delivery includes direct application to the affected tissue or region of the body.
  • topical administration comprises administering a lotion, a solution, an emulsion, a cream, a balm, an oil, a paste, a stick, an aerosol, a foam, a jelly, a foam, a mask, a pad, a powder, a solid, a tincture, a butter, a patch, a gel, a spray, a drip, a liquid formulation, an ointment to an external surface of a surface, such as a skin.
  • delivery comprises injection, such as, for example, parenchymal injection, intracistemal injection, intraarterial injection, intracistemal injection, intramuscular injection, intraparenchymal injection, intraperitoneal injection, intraspinal injection, intrathecal injection, intravenous injection, intraventricular injection, stereotactic injection, subcutaneous injection, epidural, or any combination thereof.
  • delivery is by parenteral administration, such as, for example, an intravenous administering, an intra-arterial administering, an intrathecal administering, an intraocular administering, an otic administering, an intracerebroventricular administering, or an intraperitoneal administering.
  • delivery is from a device, such as a pump, an infusion pump, or a combination thereof. In some embodiments, delivery is by an enema, an eye drop, a nasal spray, or any combination thereof.
  • a subject can administer the composition in the absence of supervision. In some embodiments, a subject can administer the composition under the supervision of a medical professional. In some embodiments, a medical professional administers the composition. In some embodiments, administering can be oral ingestion, such as, for example, comprising ingestion of a tea, an elixir, a food, a drink, a beverage, a syrup, a liquid, a gel, a capsule, a tablet, an oil, a tincture, or any combination thereof.
  • delivery can be by a capsule or a tablet.
  • the capsule comprises hydroxymethylcellulose, gelatin, hydroxypropylmethyl cellulose, pullulan, or any combination thereof.
  • capsules can comprise a coating, for example, an enteric coating.
  • capsules are vegetarian vegan, such as a hypromellose capsule.
  • delivery comprises inhalation by an inhaler, a diffuser, a nebulizer, a vaporizer, or a combination thereof.
  • administration is intermittent.
  • the compositions described herein is administered at a first time point and a second time point.
  • Administration or application of a composition disclosed herein can be performed for a treatment duration of about at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 consecutive or nonconsecutive days.
  • the treatment is administered or applied once, twice, or no more than a few times during the life of the subject.
  • the treatment is administered or applied periodically.
  • the treatment may be administered or applied approximately once a week for the lifetime of the subject.
  • the treatment may be administered or applied at different intervals, such as one injection approximately every few days for about one, two, three, or four months, or one injection about every one, two, three, or four months.
  • a treatment duration can be from about 1 to about 30 days, from about 2 to about 30 days, from about 3 to about 30 days, from about 4 to about 30 days, from about 5 to about 30 days, from about 6 to about 30 days, from about 7 to about 30 days, from about 8 to about 30 days, from about 9 to about 30 days, from about 10 to about 30 days, from about 11 to about 30 days, from about 12 to about 30 days, from about 13 to about 30 days, from about 14 to about 30 days, from about 15 to about 30 days, from about 16 to about 30 days, from about 17 to about 30 days, from about 18 to about 30 days, from about 19 to about 30 days, from about 20 to about 30 days, from about 21 to about 30 days, from about 22 to about 30 days, from about 23 to about 30 days, from about 24 to about 30 days, from about 25 to about 30 days, from about 26 to about 30 days, from about 27 to about 30 days, from about 28 to about 30 days, or from about 29 to about 30 days.
  • Administration or application of a composition disclosed herein can be performed for a treatment duration of at least about 1 week, at least about 1 month, at least about 1 year, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years, at least about 6 years, at least about 7 years, at least about 8 years, at least about 9 years, at least about 10 years, at least about 15 years, at least about 20 years, or more.
  • Administration can be performed repeatedly over a lifetime of a subject, such as once a month or once a year for the lifetime of a subject.
  • Administration can be performed repeatedly over a substantial portion of a subject’s life, such as once a month or once a year for at least about 1 year, 5 years, 10 years, 15 years, 20 years, 25 years, 30 years, or more.
  • Administration or application of composition disclosed herein can be performed at least 1, 2, 3, 4, 5, or more times a day. In some embodiments, administration or application of composition disclosed herein is performed at least 1, 2, 3, 4, 5, 6, 7, or more times in a week. In some embodiments, administration or application of composition disclosed herein is performed at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more times a month. In some embodiments, administration is continuous or essentially continuous over a preselected period of time. In some embodiments, administration is local. In some embodiments, administration is systemic.
  • exogenous genetic material e.g., encoding one or more engineered tRNAs
  • exogenous genetic material is introduced into a cell in vivo by genetic transfer methods, such as transfection or transduction, to provide a genetically modified cell.
  • transfection techniques include, but are not limited to, calcium phosphate DNA co-precipitation; DEAE-dextran; electroporation; cationic liposome-mediated transfection; tungsten particle-facilitated microparticle bombardment; and/or strontium phosphate DNA co-precipitation.
  • the engineered tRNA of the present invention is packaged in a kit.
  • a kit comprises an engineered tRNA.
  • a kit can comprise a composition described herein and a container.
  • a kit comprises a pharmaceutical composition, which can comprise an engineered tRNA, a polynucleotide (e.g., vector) encoding the engineered tRNA, or both.
  • a kit comprises a pharmaceutical composition described herein (e.g. an engineered tRNA and a pharmaceutically acceptable excipient, carrier or diluent, optionally in a dose unit form) .
  • a kit comprises a packaging or a container.
  • kits comprises packaging.
  • the kit can comprise a container.
  • the container can be made of plastic, glass, metal, or any combination thereof.
  • a kit can comprise instructions for use, such as instructions for administration to a subject.
  • a packaged product comprising a composition described herein comprises labels.
  • the pharmaceutical composition described herein is manufactured according to current good manufacturing practice (cGMP) and applicable labeling regulations.
  • cGMP current good manufacturing practice
  • a pharmaceutical composition and/or kit disclosed herein can be aseptic.
  • kits Some embodiments relate to one or more methods of making a kit.
  • the method includes contacting the composition with a packaging or container.
  • the method includes contacting the composition with a packaging.
  • the method can includes contacting the composition with a container.
  • Example 1 GENERATION OF ENGINEERED TRNAS AND APPLICATION OF PLASMID-DELIVERED ENGINEERED SUPPRESSOR tRNAS FOR RECOVERY OF PTC-CONTAINING PROTEINS
  • Example 2 describes screening of engineered tRNAs for carrying an arginine that recognize a UGA/TGA stop codon. It also illustrates the use of plasmids to deliver various engineered suppressor tRNAs, enabling the restoration of full-length NanoLuc and p53 proteins containing PTCs.
  • the cassette encoding engineered suppressor tRNAs consisted of a U6 promoter, an engineered suppressor tRNA, and a poly T tail.
  • the engineered suppressor tRNAs are derived from various human non-intron and intron-spliced Arginine tRNAs including tRNA-Arg-ACG-1-1 (TRR-ACG1-1, HGNC: 34964) , tRNA-Arg-ACG-2-1 (TRR-ACG2-1, HGNC: 34664) , tRNA-Arg-CCG-1-1 (TRR-CCG1-1, HGNC: 34933) , tRNA-Arg-CCG-2-1 (TRR-CCG2-1, HGNC: 12346) , tRNA-Arg-TCG-1-1 (TRR-TCG1-1, HGNC: 34827) , tRNA-Arg-TCG-2-1 (TRR-TCG2-1, HGNC: 34979) , tRNA-Arg-TCG-3-1 (T
  • the engineered suppressor tRNA sequences are provided as SEQ ID NO: 1 to SEQ ID NO: 27.
  • the original human non-intron and intron-spliced Arginine tRNA sequences are provided as SEQ ID NO: 28 to SEQ ID NO: 47.
  • the name of engineered suppressor tRNAs and their corresponding original human Arginine tRNAs are listed in Table 1.
  • the cassettes were assembled into the parental plasmid pSpCas9 (BB) -2A-GFP (PX458) by replacing the gRNA cassettes.
  • the resulting plasmids were further constructed by removal of Cas9 cassette and the AAV2 ITR sequence.
  • the DNA sequence of parental plasmid pSpCas9 (BB) -2A-GFP (PX458) is provided as SEQ ID NO: 48.
  • the DNA sequence of constructed suppressor tRNA plasmid ptRNA-GFP is provided as SEQ ID NO: 49.
  • the engineered suppressor tRNA expression plasmids were further generated by replacing the region indicated by the dashed line shown in the portion of the plasmid ptRNA-GFP highlighted in grey in SEQ ID NO: 49) with individual engineered suppressor tRNA sequences as listed in SEQ ID NO: 1-27 and 61-81.
  • the constructed suppressor tRNA plasmid ptRNA-GFP-R3-147 sequence with engineered suppressor tRNA R3-147 (which originated from human tRNA-Arg-TCT-1-1) is provided as SEQ ID NO: 50.
  • the remaining EGFP expression cassette was used as a loading control to monitor the plasmid expression status after cell transfection.
  • a scrambled sequence Scr1-4 (also referred to as “Scr” ) derived from the suppressor tRNA R3-147 was constructed into the plasmid ptRNA-GFP-R3-147 by replacing the engineered suppressor tRNA R3-147.
  • the RNA sequence of Scr1-4 is provided as SEQ ID NO: 51.
  • the engineered suppressor tRNA screening was carried out in two HEK293 cell lines: Luc_V2_R3 and Luc_V3_R3, each of which stably expressed a different modified NanoLuc luciferase.
  • These modifications include the insertion of stop codon TGA after 195 bp or 474bp in the NanoLuc luciferase gene in the Luc_V2_R3 and Luc_V3_R3 cells, respectively, resulting the premature termination codon and truncated non-functional NanoLuc luciferase, as shown in FIG. 1A.
  • the modified UGA-containing NanoLuc luciferases were fused with 3x Myc and 3x FLAG at their N-and C-termini, respectively.
  • the DNA sequence encoding the modified NanoLuc Luc_V2_R3 and Luc_V3_R3 are provided as SEQ ID NO: 52 and SEQ ID NO: 53, respectively.
  • HEK293 cell lines stably expressing a different modified NanoLuc luciferase in which the premature TGA stop codon was replaced with the glycine-coding codon GGA were used as the corresponding positive control, named Luc_V2_R4 (also referred to as V2_R4) , and Luc_V3_R4 (also referred to as V3_R4) , respectively.
  • the DNA sequence encoding the modified NanoLuc Luc_V2_R4 and Luc_V3_R4 are provided as SEQ ID NO: 54 and SEQ ID NO: 55, respectively.
  • the Western Blot and RT-qPCR were carried out in DMS114 cells and Calu6 cells that comprised the premature UGA stop codon in the p53 mRNA.
  • the DMS114 cells contained a homozygous nonsense mutation resulting in the transition of arginine codon into a UGA stop codon, and a truncated p53 protein 212 amino acid in length.
  • the Calu6 cells contained an arginine codon mutated into a UGA stop codon, resulting a truncated p53 protein 195 amino acids in length.
  • A549 cells were used as the positive control, as they expressed the wild-type p53 protein.
  • the cells were seeded with 1 ⁇ 10 4 cells/well in a 96-well plate in 100 ⁇ L high glucose DMEM supplemented with 10%FBS and 2 mM L-Glutamine. Once the confluency reached 80%, the cells were transfected with suppressor tRNA plasmids using HD Transfection Reagent (Promega) according to the manufacturer’s instructions. The mixture of the HD Transfection Reagent and DNA in the ratio of 3: 1 was incubated at room temperature for 10 min, and 5 ⁇ L of the mixture was added into cells in a 96-well plate containing 100 ⁇ l of medium per well. The plasmid with scrambled sequence Scr1-4 was used as a negative control.
  • HD Transfection Reagent Promega
  • the NanoLuc luciferase assay was carried out with Luciferase Assay System (Promega) according to the manufacturer’s instructions.
  • Luciferase Assay Reagent was prepared freshly by mixing 1 volume of Luciferase Assay Substrate with 50 volumes of Luciferase Assay Buffer.
  • the cell culture plate was equilibrated at room temperature for 10 min, and 100 ⁇ L of Luciferase Assay Reagent was added into each well. After consistent shaking at room temperature for 5 min in the dark, the mixture was further transferred into white solid plate (Greiner) .
  • the luminescence was detected by SpectaMax i3x plate reader (Molecular Devices) with endpoint mode and 200 ms integration time.
  • the cells were scraped in the presence of 1 mL of TRIzol TM Reagent (Thermofisher Scientific: 15596026) and incubated for 5 min at room temperature. Cell debris were removed by centrifugation for 5 min at 12,000 g and 4 °C, the supernatant was transferred into a new tube containing 0.2 mL of chloroform and mixed thoroughly by shaking. After 5 min incubation at room temperature and 15 min centrifugation at 12,000 g and 4 °C, the mixture was separated into three phases. The upper aqueous phase was then transferred into a new tube containing 0.5 mL of isopropanol and mixed by vortexing.
  • TRIzol TM Reagent Thermofisher Scientific: 15596026
  • RNA was precipitated by centrifugation for 10 min at 12,000 g and 4 °C.
  • the RNA pellet was further washed by 1 mL of 75 %ethanol, air dried, and resuspended in 50 ⁇ L of RNase-free water.
  • the RNA was further treated with DNase I (New England Biolabs, M0303S) to remove potential DNA contamination and stored in -80 °C.
  • RNA concentration was determined by nanodrop, and equal amounts of RNAs were reverse-transcribed with PrimeScript RT Reagent Kit (TAKARA, RR037A) according to the manufacturer’s instructions.
  • the obtained cDNAs were then used for gene expression quantification with TB Green Premix Ex Taq II (TAKARA, RR82WR) according to the manufacturer’s instructions.
  • the qPCR was performed on the 480 System (Roche) , and the program was set up as: pre-denaturing step at 95 °C for 30 seconds, 40 times of amplification cycle including denaturing at 95 °C for 5 seconds and annealing plus extending at 60 °C for 30 seconds.
  • the primers used for the qPCR are listed in Table 4.
  • tRNA-Arg-TCT-2-1, tRNA-Arg-TCT-3-1, tRNA-Arg-TCT-4-1 and tRNA-Arg-TCT-5-1 were engineered and synthesized with substitution of the native anticodon with the tri-nucleotide UCA, which can base pair with the stop codon UGA.
  • suppressor tRNAs R3-1, R3-2, R3-3, R3-4, R3-5, R3-6, R3-7, R3-8, R3-9, R3-10, R3-11, R3-12, R3-13, R3-14, R3-15, R3-147, R3-148, R3-149, R3-150 and R3-151 were further cloned into suppressor tRNA plasmid ptRNA-GFP (SEQ ID NO: 49) by replacing the dashed line shown in SEQ ID NO: 49 with individual suppressor tRNA, which were then transfected into NanoLuc reporter cell lines Luc_V2_R3 and Luc_V3_R3 for a NanoLuc luciferase assay as depicted in FIG.
  • R3-8 and R3-147 derived from human tRNA-Arg-CCT-4-1 and tRNA-Arg-TCT-1-1, respectively, showed the highest luciferase activities in both NanoLuc reporter cell lines (FIGS. 1B-1C) , whereas the negative control transfected with Scr1-4 exhibited minor luciferase activity.
  • Engineered tRNA “M2” (FIG. 2C, also referred to as R3-147-M2) has a C at the 4th nucleotide 3’ to the anticodon (labeled as nucleic acid position 40) , while R3-147 has a U at position 40 (FIG. 2B) .
  • Engineered tRNA “M3” (FIG.
  • Engineered tRNA “M4” (FIG. 2E, also referred to as R3-147-M4) has a G at the 1st nucleotide 3’ to the anticodon (labeled as position 37) , while R3-147 has an A at position 37 (FIG. 2B) .
  • Engineered tRNA “M5” (FIG. 2F, also referred to as R3-147-M5) has the modifications of both M2 and M3.
  • Engineered tRNA “M6” (FIG. 2G, also referred to as R3-147-M6) has the modifications of both M2 and M4.
  • Engineered tRNA “M7” (FIG. 2H, also referred to as R3-147-M7) has the modifications of both M3 and M4.
  • Engineered tRNA “M8” (FIG. 2I, also referred to as R3-147-M8) has the modifications of M2, M3, and M4.
  • M2, M3, M4, M5, and M7 demonstrated nearly or more than a 2-fold increase in PTC read-through efficiency, indicating that modifications at these specific sites significantly enhance the suppressor tRNAs'capability to overcome PTCs.
  • M6 and M8 showed relatively weaker improvements in PTC read-through efficiency, likely due to the simultaneous alteration of the 1st and 4th nucleotides 3’ to the anticodon, which may diminish the enhancement achieved by individual modifications.
  • M54 (FIG. 2Q, also referred to as R3-147-M54)
  • M55 (FIG. 2R, also referred to as R3-147-M55)
  • M56 (FIG. 2S, also referred to as R3-147-M56)
  • M57 (FIG. 2T, also referred to as R3-147-M57)
  • M58 (FIG. 2U, also referred to as R3-147-M58)
  • M59 (FIG. 2V, also referred to as R3-147-M59)
  • M62 (FIG. 2W, also referred to as R3-147-M62)
  • M63 (FIG.
  • NanoLuc luciferase assays revealed that M54 exhibited approximately 11 times the read-through efficiency of R3-147 (Figure 4A) . In contrast, M2 showed only about twice the read-through efficiency of R3-147 in the same assay (FIG. 1H) . This indicates that these additional modifications significantly enhance the suppressor tRNA's ability to overcome PTCs.
  • engineered tRNAs demonstrated increased PTC suppression efficiency compared to R3-147 in the NanoLuc luciferase assay.
  • engineered tRNAs M23, M26, and M108 exhibited more than twice the luciferase activity of R3-147.
  • Engineered tRNA M55 displayed about 7-times greater activity.
  • Engineered tRNAs M54, M59, M63, and M67 showed approximately 12-times greater activity.
  • Engineered tRNA M62 exhibited about 18-times greater activity, and engineered tRNA M65 showed about 30-times greater activity (FIG. 4A) .
  • the following example describes the determination of the amino acid carried by the engineered suppressor tRNA recognizing a UGA/TGA stop codon.
  • the cells were scraped in the presence of ice-cold RIPA lysis buffer (Sangon Biotech) supplemented with protease inhibitor cocktail (Roche) and benzonase (Sigma) , and then lysed on ice for 10 minutes.
  • the supernatant (whole cell extract, WCE) was collected after centrifugation at 12,000 g for 10 minutes at 4°C.
  • the anti-FLAG Magnetic Beads (Thermo Scientific) were equilibrated at room temperature and then washed three times with the lysis buffer. The whole cell extract was incubated with the anti-FLAG Magnetic Beads at room temperature with mixing for 30 minutes.
  • the supernatant (flow-through, FT) was collected, and the beads were washed twice with PBS and once with water. Subsequently, the protein bound to the beads was eluted with 50 ⁇ L of 2x SDS-PAGE Sample Buffer and denatured at 95°C for 10 minutes with rotation at 1000 rpm. The supernatant (immunoprecipitated, IP) was collected, flash-frozen in liquid nitrogen, and stored at -80°C.
  • MS mass spectrometry
  • HPLC HPLC 1000, Thermo Fisher Scientific
  • Q Exactive mass spectrometer
  • SEQ ID NO: 56 The amino acid sequence of the full-length modified NanoLuc protein is provided as SEQ ID NO: 56.
  • the potentially generated proteins after PTC readthrough were created by replacing the region indicated by the dashed line in the modified NanoLuc protein (highlighted in grey in SEQ ID NO: 56) with one of the 20 different amino acids.
  • an exemplary amino acid sequence of the full-length modified NanoLuc protein, which incorporates the amino acid arginine is provided as SEQ ID NO: 57.
  • Parameters included a maximum of 2 missed cleavages, 20 PPM peptide mass tolerance, 0.1 Da fragment mass tolerance, and trypsin digestion, with Carbamidomethyl (C) specified as the fixed modification and Oxidation (M) as the variable modification.
  • C Carbamidomethyl
  • M Oxidation
  • the resulting dataset was further analyzed at the peptide level, considering only peptides with Andromeda scores greater than 40.
  • the fraction of amino acids carried by the engineered suppressor tRNA was determined by comparing the intensity of peptides with specific amino acid insertions to the total intensity of all peptides containing an
  • NanoLuc protein after PTC readthrough incorporates the amino acid arginine at the desired position
  • Luc-V2-R3 cells were transfected with plasmids containing various engineered suppressor tRNAs. These cells carry the NanoLuc gene with a PTC, which, when read through by the engineered suppressor tRNAs, produces full-length NanoLuc protein fused with a C-terminal FLAG tag (FIG. 1A, top panel) . After immunoprecipitation, the resulting immunoprecipitated protein samples were analyzed via Western blot. As shown in FIG. 1P, the full-length modified NanoLuc protein was significantly more abundant in the immunoprecipitation (IP) samples compared to the whole cell extract (WCE) samples.
  • IP immunoprecipitation
  • WCE whole cell extract
  • RNA isolation from cells was performed following the protocol provided with the RNAiso for Small RNA Kit (Takara, 9753A) , adhering to the manufacturer’s guidelines.
  • the concentration of small RNA was measured using a Nanodrop spectrophotometer and stored at -80°C.
  • RNA sequencing and RNA sequencing using an Illumina sequencer were conducted according to industry standards.
  • the obtained sequencing data underwent rigorous quality assessment using FastQC software and cleaning with Trimmomatic software.
  • the cleaned data were then compared to a tRNA reference sequence ( https: //gtrnadb. ucsc. edu/index. html , Homo sapiens (GRCh38/hg38) ) , which includes all human tRNA sequences with CCA attached at the 3' end, using Bowtie2 software.
  • tRNAs were categorized based on their characteristics into isodecoders (tRNAs with the same anticodon) and isoacceptors (tRNAs carrying the same amino acid) for statistical analysis.
  • the suppressor tRNAs are expressed and present in full-length form
  • the plasmids containing the suppressor tRNAs were transfected into the NanoLuc reporter cell line Luc_V2_R3, and all the tRNAs were isolated and analysed following the method outlined by Hu et al. (2021) (Hu, J. et al. (2021) . “Quantitative mapping of the cellular small RNA landscape with AQRNA-seq. ” Nature biotechnology. 39: 8: 978-988. doi: 10.1038/s41587-021-00874-y. PMID: 33859402) .
  • the engineered suppressor tRNA R3-8 was expressed in cells transfected with the R3-8 plasmid, whereas no R3-8 signal was detected in cells transfected with other plasmids.
  • the engineered suppressor tRNA R3-147 was only expressed in cells transfected with the R3-147 plasmid, as shown in the right panel of FIG. 1I.
  • the modified suppressor tRNA M2-M8 were also subjected to tRNA sequencing. As shown in the left panel of FIG. 1T, the engineered suppressor tRNA R3-147 was detected in cells transfected with both the R3-147 and M3 plasmids. This finding is due to R3-147 and M3 having identical sequences after transcription and maturation in the cells. The tRNA R3-147 signal in cells transfected with the M3 plasmid was notably higher than in cells transfected with the R3-147 plasmid, suggesting that the addition of the CCA sequence at the DNA level enhances the abundance of exogenous tRNA in cells.
  • Sequencing of cells transfected with Scr1-4 revealed very low expression levels of Scr1-4 (FIG. 1U, right panel) , with reads only slightly above the lower limit of detection (LLOD) . While some Scr1-4 sequence signals were detected in cells transfected with engineered suppressor tRNAs, these were very low and below the LLOD, thus considered background noise. Furthermore, as shown in FIG. 1V, endogenous tRNA Arg-TCT-1-1 corresponding to the engineered suppressor tRNAs was detected in all transfected cells, with expression levels similar to those in cells transfected with the Scr1-4 negative control. This confirmed that modifications to tRNA did not affect the levels of endogenous related tRNAs.
  • the remarkably successful suppressor tRNA M54 which demonstrated approximately a 12-fold increase in luminescence signal compared to R3-147, was also analyzed through tRNA sequencing. As shown in FIG. 1J, expression of the engineered suppressor tRNA M54 was observed only in cells transfected with the M54 plasmid, and it was present in its full-length form with no fragments. Additionally, the corresponding endogenous tRNA Arg-TCT-1-1 was detected in the transfected cells (FIG. 1K, right panel) , with expression levels comparable to those in cells transfected with Scr1-4 or treated with water ("Blank") as negative controls. Notably, the expression level of M54 was approximately 6-times higher than that of R3-147 (FIG. 1I, right panel) and about 10-times higher than the corresponding endogenous tRNA Arg-TCT-1 (FIG. 1K, right panel) .
  • suppressor tRNAs maintains the homeostasis of mature cytoplasmic tRNAs
  • the following example illustrates the use of lentiviruses to deliver various engineered suppressor tRNAs, thereby restoring the function of the NanoLuc protein containing a PTC.
  • the cell line Luc_V2_R3 was digested with 0.25%trypsin and plated into 24-well plates at a density of 10,000 cells per well for lentivirus transduction after 24 hours. Based on the provided virus infection titer, the required amounts of lentiviruses LV_R3-5, LV_R3-8 and LV_R3-147 were calculated to achieve MOI (multiplicity of infection) of 2 and 20.
  • the viruses were diluted in 0.5 mL DMEM medium with 2%FBS, and polybrene was added to a final concentration of 8 ⁇ g/mL. The original medium was discarded, the virus-containing medium was added individually, and the cells were incubated overnight at 37°C in a 5%CO2 cell culture incubator. After 24 hours, replace the medium with fresh normal medium and perform NanoLuc luciferase assays 48 hours later.
  • NanoLuc luciferase assay was conducted following the methodology outlined in Example 1.
  • FCM Flow Cytometry
  • the GFP expression levels were analyzed using a flow cytometer. For each sample, 10,000 cells were gated based on forward light scatter. The GFP fluorescence signal was collected through a 488 nm band-pass filter, and the GFP fluorescence intensity was defined as the GFP-A(green fluorescence signal) mean of 10,000 cells. P1 and P2 regions were determined to separate the lower fluorescence cluster (P1) from the higher fluorescence cluster (P2) . P1 cell clusters were defined as GFP-non-expressing cells, while P2 cell clusters were defined as GFP-expressing cells. The percentage of P2 cell clusters represented the transduction efficiency of the lentivirus.
  • the lentivirus-delivered engineered tRNAs restores function of NanoLuc protein containing a PTC
  • the lentiviral vector RNA sequence (SEQ ID NO: 58) was modified by replacing the region marked with dashed lines and highlighted in gray with the reverse complementary RNA sequences of the engineered suppressor tRNAs R3-5 (FIG. 3A, corresponding to SEQ ID NO: 13) , R3-8 (FIG. 3B, corresponding to SEQ ID NO: 16) , and R3-147 (FIG. 2B, corresponding to SEQ ID NO: 1) .
  • the vector included a green fluorescent protein (GFP) expression cassette as a marker for monitoring transduction efficiency.
  • GFP green fluorescent protein
  • Example 5 APPLICATION OF ENGINEERED SUPPRESSOR TRNAS ON READING THROUGH OF PTC IN THE COL4A5 GENE ASSOCIATED WITH ALPORT SYNDROME
  • Example 2 describes the surprising ability of engineered suppressor tRNA to restore mRNA and protein levels of the COL4A5 (COLLAGEN IV ALPHA V) gene containing a PTC in in-vitro lentivirus assays.
  • the PTC in the COL4A5 gene can induce Alport syndrome.
  • the A549 cell line was selected for generating PTC cell lines as COL4A5 R373*, where the codon coding arginine at position 373 was mutated to a stop codon. Additionally, another PTC cell line, COL4A5 R1563*, was created by changing the codon coding arginine at position 1563 to a stop codon.
  • These cell lines-A549, A549 COL4A5 R373*, and R1563*- were cultured in DMEM (Thermo Fisher Scientific) supplemented with 10%FBS (Thermo Fisher Scientific) .
  • the A549 and COL4A5 PTC cell lines were digested with 0.25%trypsin and plated into 24-well plates at a density of 30,000 cells per well for lentivirus transduction after 24 hours. Based on the provided virus infection titer, the required amounts of lentiviruses LV_R3-147 and LV_R3-147-M54 were calculated to achieve an MOI (multiplicity of infection) of 20.
  • the viruses were diluted in 0.5 mL DMEM medium with 2%FBS, and polybrene was added to a final concentration of 8 ⁇ g/mL. The original medium was discarded, the virus-containing medium was added individually, and the cells were incubated overnight at 37°C in a 5%CO2 cell culture incubator.
  • the virus-containing medium was replaced, and the cells were transferred to a 6-well plate. Puromycin was added to the medium at a final concentration of 1 ⁇ g/mL to select for cells with integrated lentivirus. Once the cells were growing stably, they were cultured in normal medium for further experiments.
  • Total RNA extraction from cells was performed following the protocol provided with the Total RNA Miniprep Kit (New England Biolabs, T20120S) , adhering to the manufacturer’s guidelines. Subsequently, the RNA underwent DNase I treatment (New England Biolabs, M0303S) to eliminate potential DNA contamination. The concentration of total RNA was measured using a Nanodrop spectrophotometer and stored at -80°C.
  • RNA was reverse-transcribed using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, 4368814) following the manufacturer’s protocol.
  • the resulting cDNAs were then utilized for gene expression quantification employing the TaqMan TM Fast Advanced Master Mix (Thermo Fisher Scientific, 4444556) according to the manufacturer’s instructions.
  • Quantitative PCR quantitative PCR (qPCR) was conducted on the 480 System (Roche) , with the following program setup: a pre-denaturation step at 95 °C for 30 seconds, followed by 40 cycles of amplification comprising denaturation at 95 °C for 5 seconds and annealing plus extension at 60 °C for 30 seconds.
  • the primers utilized for the qPCR are detailed in Table 6.
  • Cells were plated at a density of 50,000 cells per well in a 24-well plate and incubated in a 5%CO2 cell incubator at 37°C for 24 hours. Subsequently, the cells were fixed with 500 ⁇ L of 4%paraformaldehyde (in PBS, pH 7.4) for 10 minutes and washed three times for 10 minutes each with 500 ⁇ L of ice-cold PBS. Afterward, the cells were permeabilized with 500 ⁇ L of PBS containing 0.1%Triton-X 100 for 10 minutes and washed three times for 10 minutes each with 500 ⁇ L of PBS. To block nonspecific antibody binding, the cells were treated with 500 ⁇ L of PBS containing 10%goat serum for one hour.
  • PBS 4%paraformaldehyde
  • the cells were incubated overnight at 4°C with the primary antibody Anti-COL4A5 H53 (Table 3) at a 1: 500 dilution in PBS containing 10%goat serum. After washing three times for 10 minutes each with PBST (PBS + 0.1%Tween 20) , the cells were incubated with the secondary antibody Goat anti-Rat AF647 (Table 3) at a dilution of 1: 1000 in PBS for 1 hour in the dark at room temperature.
  • the cells were washed three times for 10 minutes each with PBST, and the nuclei were stained with Hoechst 33342 at a dilution of 1: 200 in PBST for 5 minutes. After three additional washes for 10 minutes each with PBST, the cells were stored at 4°C in 500 ⁇ L of PBS solution. Immunofluorescence signals were visualized using a confocal microscope (Nikon) . ImageJ software was utilized to analyze the integrated density of the COL4A5 signal, and to count the cells based on the Hoechst 33342 signal.
  • the lentivirus-delivered engineered suppressor tRNA restores mRNA levels of COL4A5 gene containing PTCs
  • the lentiviral vector RNA sequence (SEQ ID NO: 58) was modified by replacing the region marked with dashed lines and highlighted in gray with the reverse complementary RNA sequences of the engineered suppressor tRNAs R3-147 (FIG. 2B, corresponding to SEQ ID NO: 1) and R3-147-M54 (FIG. 2Q, corresponding to SEQ ID NO: 72) .
  • the vector included a puromycin resistance gene (PuroR) as a selection marker. The lentivirus encapsulating this vector was then used in experiments.
  • PuroR puromycin resistance gene
  • the mRNA levels in the COL4A5 R1563*cell line transduced with the lentivirus carrying the engineered suppressor tRNA increased.
  • cells transduced with LV_R3-147 showed an approximate 1-fold increase in COL4A5 mRNA levels, reaching about one-quarter of the normal mRNA levels found in wild-type A549 cells.
  • Cells transduced with LV_R3-147-M54 exhibited an approximate 3-fold increase in COL4A5 mRNA levels, achieving about 60%of the normal mRNA levels in wild-type A549 cells. Consistent with the NanoLuc luciferase assay results, M54 exhibited a much higher readthrough capability for the PTC compared to R3-147.
  • the lentivirus-delivered engineered suppressor tRNA restores full-length protein level of COL4A5 gene containing PTC
  • the following example illustrates the use of AAVs with different strand types and serotypes to deliver engineered suppressor tRNA, thereby restoring the function of the NanoLuc protein containing a PTC.
  • the NanoLuc reporter cell line Luc-V2-R3 was digested with 0.25%trypsin and plated into 24-well plates at a density of 10, 000 cells per well for AAV transduction after 24 hours. Based on the provided virus physical titer, the required amounts of AAV were calculated to achieve a series of MOI (multiplicity of infection) gradients, ranging from 2.00E+05 to 2.5E+04 vg/cell for ssAAV2/9 and 5.00E+04 to 1.25E+04 vg/cell for scAAV2/9. The viruses were diluted in 0.2 mL of DMEM medium with 2%FBS. The original medium was discarded, and the virus-containing medium was individually added to each well.
  • MOI multiplicity of infection
  • the cells were incubated at 37°C in a 5%CO2 cell culture incubator for 1 hour, after which another 0.3 mL of DMEM medium with 20%FBS was added to each well. The plate was then incubated at 37°C in a 5%CO2 cell culture incubator for another 72 hours before detection.
  • NanoLuc luciferase assay was conducted following the methodology outlined in Example 1.
  • FCM Flow Cytometry
  • the mCherry expression levels were analyzed using a flow cytometer. For each sample, 10,000 cells were gated based on forward light scatter. The mCherry fluorescence signal was collected through a 587 nm band-pass filter, and the mCherry fluorescence intensity was defined as the mCherry-A (red fluorescence signal) mean of 10,000 cells. P1 and P2 regions were determined to separate the lower fluorescence cluster (P1) from the higher fluorescence cluster (P2) . P1 cell clusters were defined as mCherry-non-expressing cells, while P2 cell clusters were defined as mCherry-expressing cells. The percentage of P2 cell clusters represents the transduction efficiency of AAV.
  • the scAAV2/9-delivered engineered tRNAs restores function of NanoLuc protein containing a PTC
  • the self-complementary AAV (scAAV) vector DNA sequence (SEQ ID NO: 60) was modified by replacing the regions marked with dashed lines and highlighted in gray with the DNA sequences of the engineered suppressor tRNAs R3-5 (FIG. 3A, corresponding to SEQ ID NO: 13) , R3-8 (FIG. 3B, corresponding to SEQ ID NO: 16) , and R3-147 (FIG. 2B, corresponding to SEQ ID NO: 1) .
  • the ssAAV2/9-delivered engineered suppressor tRNA restores function of NanoLuc protein containing a PTC
  • the single-stranded AAV (ssAAV) vector DNA sequence (SEQ ID NO: 59) was modified by replacing the regions marked with dashed lines and highlighted in gray with the DNA sequences of the engineered suppressor tRNAs R3-147 (FIG. 2B, corresponding to SEQ ID NO: 1) and R3-147-M54 (FIG. 2Q, corresponding to SEQ ID NO: 72) .
  • the vector included a red fluorescent protein (mCherry) expression cassette as a marker to monitor transduction efficiency.
  • Luc-V2-R3 cell lines infected with ssAAV2/9 carrying various engineered suppressor tRNAs all exhibited a portion of mCherry positive cells and displayed luciferase activities, indicating successful transduction and suppressor tRNA expression with the ssAAV vector.
  • MOI the proportion of mCherry positive cells and the luciferase activities gradually decreased, implying a correlation between suppression efficiency and the quantity of engineered suppressor tRNAs expressed by ssAAV2/9 transduced into the cells.
  • Example 7 APPLICATION OF ENGINEERED SUPPRESSOR tRNAs DELIVERED BY AAV IN THE TREATMENT OF A MOUSE MODEL WITH ALPORT SYNDROME
  • the ssAAV2/9-delivered engineered suppressor tRNA decreases the relative ratio of urinary albumin to creatinine
  • mice COL4A5-R471*/Y Male PTC mice COL4A5-R471*/Y, aged 4 weeks, received intravenous injections via the tail vein of the ssAAV2/9-coated vector ssAAV-2xU6 (FIG. 4D) , containing nucleotide sequences encoding the engineered suppressor tRNAs R3-147 or R3-147-M54 (corresponding to SEQ ID NO: 1 or SEQ ID NO: 72, respectively) .
  • Urinary albumin and creatinine levels were regularly monitored to assess symptom relief. Mice with a wild-type genetic background served as the healthy control, as depicted in FIG. 4G.
  • Embodiment 1 An engineered transfer RNA (tRNA) for carrying an arginine comprising a T-arm, a D-arm, an anticodon arm, a variable region, and an acceptor arm, wherein the anticodon-arm comprises a tri-nucleotide anti-codon, wherein the anticodon is 5’ -UCA-3’ and recognizes a UGA stop codon, wherein the engineered tRNA comprises one or more modifications relative to a tRNA having the sequence of SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16; and
  • Embodiment 2 The engineered tRNA of embodiment 1, wherein the engineered tRNA has a nucleotide sequence that is at least about 85%identical to SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16.
  • Embodiment 3 The engineered tRNA of embodiment 1 or 2, wherein the engineered tRNA contains no more than about 9 nucleotide substitutions relative to SEQ ID NO: 1, no more than about 5 nucleotide substitutions relative to SEQ ID NO: 1, no more than about 5 nucleotide substitutions relative to SEQ ID NO: 13, or no more than about 5 nucleotide substitutions relative to SEQ ID NO: 16.
  • Embodiment 4 The engineered tRNA of any one of embodiments 1-3, wherein the engineered tRNA comprises an A to G substitution at the 1st nucleotide 3’ to the anticodon.
  • Embodiment 5 The engineered tRNA of any one of embodiments 1-4, wherein the engineered tRNA comprises a U to C substitution at the 4 th nucleotide 3’ to the anticodon.
  • Embodiment 6 The engineered tRNA of any one of embodiments 1-5, wherein the engineered tRNA comprises a CCA sequence attached to the acceptor arm at the 3’ end.
  • Embodiment 7 The engineered tRNA of any one of embodiments 1-6, wherein the engineered tRNA has nucleic acid sequence selected from the group consisting of SEQ ID NOs: 2-8 and 61-64.
  • Embodiment 8 The engineered tRNA of any one of embodiments 1-7, wherein the engineered tRNA exhibits an increased PTC readthrough capability in vivo and/or in vitro as compared to a tRNA having the sequence of SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16.
  • Embodiment 9 The engineered tRNA of embodiment 8, wherein the PTC readthrough capability is determined by a NanoLuc luciferase assay, RT-qPCR, Western Blot, Immunoprecipitation, Mass Spectrometry, and/or Immunofluorescence.
  • Embodiment 10 A nucleic acid encoding the engineered tRNA of any one of embodiments 1-9.
  • Embodiment 11 A vector comprising the nucleic acid of embodiment 10.
  • Embodiment 12 The vector of embodiment 11, wherein the vector is a viral vector or a plasmid.
  • Embodiment 13 The vector of embodiment 12, wherein the vector is a viral vector, and wherein the viral vector is an adenoviral vector, an adeno-associated viral (AAV) vector, or a lentiviral vector.
  • the viral vector is an adenoviral vector, an adeno-associated viral (AAV) vector, or a lentiviral vector.
  • Embodiment 14 The vector of embodiment 13, wherein the vector is an AAV 2/2 vector, an AAV 2/5 vector, an AAV 2/6 vector, an AAV 2/7 vector, an AAV2/8 vector, or an AAV 2/9 vector.
  • Embodiment 15 A pharmaceutical composition comprising the engineered tRNA of any one of embodiments 1-9, the nucleic acid of embodiment 10, or the vector of any one of embodiments 11-14, further comprising a pharmaceutically acceptable carrier.
  • Embodiment 16 The pharmaceutical composition of embodiment 15, wherein the pharmaceutically acceptable carrier is a liposome or a lipid nanoparticle.
  • Embodiment 17 A method of restoring translation of a coding nucleic acid of interest containing a premature UGA/TGA stop codon in a cell, comprising introducing to the cell the engineered tRNA of any one of embodiments 1-9, the nucleic acid of embodiment 10, or the vector of any one of embodiments 11-14, wherein the engineered tRNA introduced into the cell or produced from the nucleic acid or vector recognizes and reads through the premature UGA/TGA stop codon, thereby restoring translation of the coding nucleic acid of interest containing the premature UGA/TGA stop codon.
  • Embodiment 18 The method of embodiment 17, wherein the engineered tRNA restores at least 5%of the translation of the coding nucleic acid of interest containing a premature UGA/TGA stop codon relative to a corresponding coding nucleic acid not containing the premature UGA/TGA stop codon.
  • Embodiment 19 A method of treating a disease associated with a premature UGA/TGA stop codon in an individual, comprising: administering to the individual an effective amount of the pharmaceutical composition of embodiment 15 or 16.
  • Embodiment 20 The method of embodiment 19, wherein the premature stop-codon-associated disease is cystic fibrosis, muscular dystrophy, Alport syndrome, Stargardt disease, dilated cardiomyopathy, ⁇ -thalassemia or Liddle's syndrome.
  • Embodiment 21 The method of embodiment 19 or 20, wherein the individual is human.
  • Embodiment 22 The engineered tRNA of any one of embodiments 1-7, wherein the engineered tRNA exhibits increased PTC readthrough efficiency in vivo as compared to a tRNA having the sequence of SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16.
  • Embodiment 23 The engineered tRNA of any one of embodiments 1-7, wherein the engineered tRNA exhibits an increased stability in vivo and/or in vitro as compared to a tRNA having the sequence of SEQ ID NO: 1, SEQ ID NO: 13, or SEQ ID NO: 16.
  • Embodiment 24 The engineered tRNA of embodiment 23, wherein the stability is determined by a proxy measurement, a half-life measurement, an amino acid charging efficiency measurement, or a measurement of binding to a docking partner elongation factor EF-Tu/EF1A1 or ribosomal machinery.
  • SEQ ID Nos 1-27 and 61-81 engineered suppressor tRNAs derived from human non-intron and intron-spliced arginine tRNA by changing the anticodon.
  • SEQ ID NO: 1 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-147 originated from intron-spliced human tRNA-Arg-TCT-1-1, from 5’ to 3’ .
  • SEQ ID NO: 2 Nucleotide (RNA) sequence of engineered suppressor tRNA M2 (also referred to as R3-147-M2) modified base on the suppressor tRNA R3-147 with substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 3 Nucleotide (RNA) sequence of engineered suppressor tRNA M3 (also referred to as R3-147-M3) modified base on the suppressor tRNA R3-147 with addition of CCA tail at the 3’ end, from 5’ to 3’ .
  • SEQ ID NO: 4 Nucleotide (RNA) sequence of engineered suppressor tRNA M4 (also referred to as R3-147-M4) modified base on the suppressor tRNA R3-147 with substitution of A with G at position 37, from 5’ to 3’ .
  • SEQ ID NO: 5 Nucleotide (RNA) sequence of engineered suppressor tRNA M5 (also referred to as R3-147-M5) modified base on the suppressor tRNA R3-147 with substitution of U with C at position 40 and addition of CCA tail at the 3’ end, from 5’ to 3’ .
  • SEQ ID NO: 6 Nucleotide (RNA) sequence of engineered suppressor tRNA M6 (also referred to as R3-147-M6) modified base on the suppressor tRNA R3-147 with substitution of U with C at position 40 and substitution of A with G at position 37, from 5’ to 3’ .
  • SEQ ID NO: 7 Nucleotide (RNA) sequence of engineered suppressor tRNA M7 (also referred to as R3-147-M7) modified base on the suppressor tRNA R3-147 with substitution of A with G at position 37 and addition of CCA tail at the 3’ end, from 5’ to 3’ .
  • SEQ ID NO: 8 Nucleotide (RNA) sequence of engineered suppressor tRNA M8 (also referred to as R3-147-M8) modified base on the suppressor tRNA R3-147 with substitution of U with C at position 40 and substitution of A with G at position 37 and addition of CCA tail at the 3’ end, from 5’ to 3’ .
  • SEQ ID NO: 9 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-1 originated from human tRNA-Arg-ACG-1-1, from 5’ to 3’ .
  • SEQ ID NO: 10 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-2 originated from human tRNA-Arg-ACG-2-1, from 5’ to 3’ .
  • SEQ ID NO: 11 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-3 originated from human tRNA-Arg-CCG-1-1, from 5’ to 3’ .
  • SEQ ID NO: 12 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-4 originated from human tRNA-Arg-CCG-2-1, from 5’ to 3’ .
  • SEQ ID NO: 13 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-5 originated from human tRNA-Arg-CCT-1-1, from 5’ to 3’ .
  • SEQ ID NO: 14 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-6 originated from human tRNA-Arg-CCT-2-1, from 5’ to 3’ .
  • SEQ ID NO: 15 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-7 originated from human tRNA-Arg-CCT-3-1, from 5’ to 3’ .
  • SEQ ID NO: 16 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-8 originated from human tRNA-Arg-CCT-4-1, from 5’ to 3’ .
  • SEQ ID NO: 17 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-9 originated from human tRNA-Arg-CCT-5-1, from 5’ to 3’ .
  • SEQ ID NO: 18 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-10 originated from human tRNA-Arg-TCG-1-1, from 5’ to 3’ .
  • SEQ ID NO: 19 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-11 originated from human tRNA-Arg-TCG-2-1, from 5’ to 3’ .
  • SEQ ID NO: 20 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-12 originated from human tRNA-Arg-TCG-3-1, from 5’ to 3’ .
  • SEQ ID NO: 21 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-13 originated from human tRNA-Arg-TCG-4-1, from 5’ to 3’ .
  • SEQ ID NO: 22 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-14 originated from human tRNA-Arg-TCG-5-1, from 5’ to 3’ .
  • SEQ ID NO: 23 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-15 originated from human tRNA-Arg-TCG-6-1, from 5’ to 3’ .
  • SEQ ID NO: 24 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-148 originated from human intron-spliced tRNA-Arg-TCT-2-1, from 5’ to 3’ .
  • SEQ ID NO: 25 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-149 originated from human intron-spliced tRNA-Arg-TCT-3-1, from 5’ to 3’ .
  • SEQ ID NO: 26 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-150 originated from human tRNA-Arg-TCT-4-1, from 5’ to 3’ .
  • SEQ ID NO: 27 Nucleotide (RNA) sequence of engineered suppressor tRNA R3-151 originated from human intron-spliced tRNA-Arg-TCT-5-1, from 5’ to 3’ .
  • SEQ ID NO: 65 Nucleotide (RNA) sequence of engineered suppressor tRNA M22 (also referred to as R3-147-M22) , which contains a substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 66 Nucleotide (RNA) sequence of engineered suppressor tRNA M23 (also referred to as R3-147-M23) , which contains a substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 67 Nucleotide (RNA) sequence of engineered suppressor tRNA M24 (also referred to as R3-147-M24) , which contains a substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 68 Nucleotide (RNA) sequence of engineered suppressor tRNA M25 (also referred to as R3-147-M25) , which contains a substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 69 Nucleotide (RNA) sequence of engineered suppressor tRNA M26 (also referred to as R3-147-M26) , which contains a substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 70 Nucleotide (RNA) sequence of engineered suppressor tRNA M46 (also referred to as R3-147-M46) , which contains a substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 71 Nucleotide (RNA) sequence of engineered suppressor tRNA M50 (also referred to as R3-147-M50) , which contains a substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 72 Nucleotide (RNA) sequence of engineered suppressor tRNA M54 (also referred to as R3-147-M54) , which contains a substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 73 Nucleotide (RNA) sequence of engineered suppressor tRNA M55 (also referred to as R3-147-M55) , which contains a substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 74 Nucleotide (RNA) sequence of engineered suppressor tRNA M56 (also referred to as R3-147-M56) , which contains a substitution of A with G at position 37, from 5’ to 3’ .
  • SEQ ID NO: 75 Nucleotide (RNA) sequence of engineered suppressor tRNA M57 (also referred to as R3-147-M57) , which contains a substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 76 Nucleotide (RNA) sequence of engineered suppressor tRNA M58 (also referred to as R3-147-M58) , which contains a substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 77 Nucleotide (RNA) sequence of engineered suppressor tRNA M59 (also referred to as R3-147-M59) , which contains a substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 78 Nucleotide (RNA) sequence of engineered suppressor tRNA M62 (also referred to as R3-147-M62) , which contains a substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 79 Nucleotide (RNA) sequence of engineered suppressor tRNA M63 (also referred to as R3-147-M63) , which contains a substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 80 Nucleotide (RNA) sequence of engineered suppressor tRNA M65 (also referred to as R3-147-M65) , which contains a substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 81 Nucleotide (RNA) sequence of engineered suppressor tRNA M67 (also referred to as R3-147-M67) , which contains a substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 61 Nucleotide (RNA) sequence of engineered suppressor tRNA M100 (also referred to as R3-147-M100) , which contains a substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 62 Nucleotide (RNA) sequence of engineered suppressor tRNA M102 (also referred to as R3-147-M102) , which contains a substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 63 Nucleotide (RNA) sequence of engineered suppressor tRNA M103 (also referred to as R3-147-M103) , which contains a substitution of U with C at position 40, from 5’ to 3’ .
  • SEQ ID NO: 64 Nucleotide (RNA) sequence of engineered suppressor tRNA M108 (also referred to as R3-147-M108) , which contains a substitution of A with G at position 37, from 5’ to 3
  • SEQ ID NOs: 28-47 are the native human endogenous tRNAs with the removal of introns, presented in the same order as their derived engineered suppressor tRNA from SEQ ID NOs: 9-27 with the exception of R3-147.
  • SEQ ID NO: 28 Nucleotide (RNA) sequence of human tRNA-Arg-ACG-1-1, from 5’ to 3’ .
  • SEQ ID NO: 29 Nucleotide (RNA) sequence of human tRNA-Arg-ACG-2-1, from 5’ to 3’ .
  • SEQ ID NO: 30 Nucleotide (RNA) sequence of human tRNA-Arg-CCG-1-1, from 5’ to 3’ .
  • SEQ ID NO: 31 Nucleotide (RNA) sequence of human tRNA-Arg-CCG-2-1, from 5’ to 3’ .
  • SEQ ID NO: 32 Nucleotide (RNA) sequence of human tRNA-Arg-CCT-1-1, from 5’ to 3’ .
  • SEQ ID NO: 33 Nucleotide (RNA) sequence of human tRNA-Arg-CCT-2-1, from 5’ to 3’ .
  • SEQ ID NO: 34 Nucleotide (RNA) sequence of human tRNA-Arg-CCT-3-1, from 5’to 3’ .
  • SEQ ID NO: 35 Nucleotide (RNA) sequence of human tRNA-Arg-CCT-4-1, from 5’ to 3’ .
  • SEQ ID NO: 36 Nucleotide (RNA) sequence of human tRNA-Arg-CCT-5-1, from 5’ to 3’ .
  • SEQ ID NO: 37 Nucleotide (RNA) sequence of human tRNA-Arg-TCG-1-1, from 5’ to 3’ .
  • SEQ ID NO: 38 Nucleotide (RNA) sequence of human tRNA-Arg-TCG-2-1, from 5’ to 3’ .
  • SEQ ID NO: 39 Nucleotide (RNA) sequence of human tRNA-Arg-TCG-3-1, from 5’ to 3’ .
  • SEQ ID NO: 40 Nucleotide (RNA) sequence of human tRNA-Arg-TCG-4-1, from 5’ to 3’ .
  • SEQ ID NO: 41 Nucleotide (RNA) sequence of human tRNA-Arg-TCG-5-1, from 5’ to 3’ .
  • SEQ ID NO: 42 Nucleotide (RNA) sequence of human tRNA-Arg-TCG-6-1, from 5’ to 3’ .
  • SEQ ID NO: 43 Nucleotide (RNA) sequence of human tRNA-Arg-TCT-1-1, from 5’ to 3’ .
  • SEQ ID NO: 44 Nucleotide (RNA) sequence of human tRNA-Arg-TCT-2-1, from 5’ to 3’ .
  • SEQ ID NO: 45 Nucleotide (RNA) sequence of human tRNA-Arg-TCT-3-1, from 5’ to 3’ .
  • SEQ ID NO: 46 Nucleotide (RNA) sequence of human tRNA-Arg-TCT-4-1, from 5’ to 3’ .
  • SEQ ID NO: 47 Nucleotide (RNA) sequence of human tRNA-Arg-TCT-5-1, from 5’ to 3’ .
  • SEQ ID NOs: 48-50 are relevant parental and constructed plasmids used herein.
  • SEQ ID NO: 48 Nucleotide (DNA) sequence of the parental plasmid pSpCas9 (BB) -2A-GFP (PX458) used for construction of engineered suppressor tRNAs expression.
  • SEQ ID NO: 49 Nucleotide (DNA) sequence of the constructed plasmid ptRNA-GFP used for engineered suppressor tRNA expression.
  • SEQ ID NO: 50 Nucleotide (DNA) sequence of the constructed plasmid ptRNA-GFP-R3-147 used for engineered suppressor tRNAs R3-147 expression.
  • SEQ ID NO: 51 Nucleotide (RNA) sequence of scrambled sequence Scr1-4 derived from the suppressor tRNA R3-147, from 5’ to 3’ .
  • SEQ ID NOs: 52-57 are modified NanoLuc nucleic acids and proteins used herein.
  • SEQ ID NO: 52 Nucleotide (DNA) sequence of the modified NanoLuc Luc_V2_R3 with premature TGA stop codon after 195bp of NanoLuc gene.
  • SEQ ID NO: 53 Nucleotide (DNA) sequence of the modified NanoLuc Luc_V3_R3 with premature TGA stop codon after 474bp of NanoLuc gene.
  • SEQ ID NO: 54 Nucleotide (DNA) sequence of the modified NanoLuc Luc_V2_R4 with glycine coding codon GGA after 195bp of NanoLuc gene.
  • SEQ ID NO: 55 Nucleotide (DNA) sequence of the modified NanoLuc Luc_V3_R4 with glycine coding codon GGA after 474bp of NanoLuc gene.
  • SEQ ID NO: 56 amino acid (protein) sequence of the full-length modified NanoLuc protein produced in the NanoLuc Luc_V2_R3 cell line after engineered suppressor tRNA readthrough, with the insertion of a specific amino acid positioned after the 65th amino acid.
  • SEQ ID NO: 57 the exemplary amino acid (protein) sequence of the full-length modified NanoLuc protein produced in the NanoLuc Luc_V2_R3 cell line after engineered suppressor tRNA readthrough, with the insertion of an amino acid arginine positioned after the 65th amino acid.
  • SEQ ID NOs: 58-60 are DNA/RNA sequences relevant to viral vectors utilized herein.
  • SEQ ID NO: 58 Nucleotide (RNA) sequence of the lentivirus LV, employed for delivering engineered tRNA expressed under the U6 promoter.
  • SEQ ID NO: 59 Nucleotide (DNA) sequence of the single-stranded AAV vector (ssAAV) carrying two copies of tRNAs, employed for delivering engineered tRNA expressed under the U6 promoter.
  • SEQ ID NO: 60 Nucleotide (DNA) sequence of the self-complementary AAV vector (scAAV) carrying one copy of tRNA, used for delivering engineered tRNA expressed under the U6 promoter
  • SEQ ID NOs: 83-88 are nucleotide (DNA) sequences related to the “fuse” tags used in the NanoLuc assays.
  • SEQ ID NO: 83 5’ fused tag (3 x Myc and GS linker) of SEQ ID NOs: 52-55.
  • SEQ ID NO: 84 3’ fused tag (3 x Flag and GS linker) of SEQ ID NOs: 52-55.
  • SEQ ID NO: 85 SEQ ID NO: 52 without fused tags.
  • SEQ ID NO: 86 SEQ ID NO: 53 without fused tags.
  • SEQ ID NO: 87 SEQ ID NO: 55 without fused tags.
  • SEQ ID NO: 88 SEQ ID NO: 54 without fused tags.
  • SEQ ID NOs: 89-92 are primers used in qPCR herein, from 5’ to 3’ .
  • SEQ ID NO:89 primer p53_forward.
  • SEQ ID NO: 90 primer p53_reverse.
  • SEQ ID NO: 91 GAPDH_forward.
  • SEQ ID NO:92 GAPDH_reverse.

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des molécules d'ARN de transfert (ARNt) modifiées qui rétablissent la traduction d'un acide nucléique codant contenant un codon d'arrêt prématuré UGA/TGA en insérant un acide aminé arginine (Arg) dans le polypeptide lors du décodage du codon UGA/TGA. La présente invention concerne également des cassettes d'expression et des vecteurs comprenant des acides nucléiques codant pour un ARNt modifié, des compositions pharmaceutiques contenant les cassettes d'expression, les vecteurs et/ou l'ARNt modifié, ainsi que des procédés de rétablissement de la traduction et/ou de traitement des maladies faisant intervenir des molécules d'ARNt modifié.
PCT/CN2024/110998 2023-08-11 2024-08-09 Molécules d'arnt suppresseurs modifiées et procédés Pending WO2025036281A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202480052068.6A CN121693567A (zh) 2023-08-11 2024-08-09 工程化抑制性tRNA分子和方法
PCT/CN2025/091495 WO2026001270A1 (fr) 2024-06-24 2025-04-27 Molécules arnt modifiées et procédés

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2023112612 2023-08-11
CNPCT/CN2023/112612 2023-08-11
CN2024100922 2024-06-24
CNPCT/CN2024/100922 2024-06-24

Publications (1)

Publication Number Publication Date
WO2025036281A1 true WO2025036281A1 (fr) 2025-02-20

Family

ID=94632179

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2024/110998 Pending WO2025036281A1 (fr) 2023-08-11 2024-08-09 Molécules d'arnt suppresseurs modifiées et procédés

Country Status (3)

Country Link
CN (1) CN121693567A (fr)
TW (1) TW202521693A (fr)
WO (1) WO2025036281A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200101174A1 (en) * 2018-09-26 2020-04-02 Case Western Reserve University Methods and compositions for treating a premature stop codon-mediated disorder
CN114908066A (zh) * 2022-05-17 2022-08-16 浙江大学 一种正交翻译系统及其在再分配密码子恢复ptc疾病中功能蛋白表达方面的应用
WO2022235861A1 (fr) * 2021-05-05 2022-11-10 Tevard Biosciences, Inc. Procédés et compositions pour traiter un trouble médié par un codon d'arrêt prématuré
CN115397983A (zh) * 2019-12-02 2022-11-25 西普治疗公司 用于治疗疾病的靶向转移rna

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200101174A1 (en) * 2018-09-26 2020-04-02 Case Western Reserve University Methods and compositions for treating a premature stop codon-mediated disorder
CN115397983A (zh) * 2019-12-02 2022-11-25 西普治疗公司 用于治疗疾病的靶向转移rna
WO2022235861A1 (fr) * 2021-05-05 2022-11-10 Tevard Biosciences, Inc. Procédés et compositions pour traiter un trouble médié par un codon d'arrêt prématuré
CN114908066A (zh) * 2022-05-17 2022-08-16 浙江大学 一种正交翻译系统及其在再分配密码子恢复ptc疾病中功能蛋白表达方面的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALBERS SUKI, ALLEN ELIZABETH C., BHARTI NIKHIL, DAVYT MARCOS, JOSHI DISHA, PEREZ-GARCIA CARLOS G., SANTOS LEONARDO, MUKTHAVARAM RA: "Engineered tRNAs suppress nonsense mutations in cells and in vivo", NATURE, SPRINGER NATURE LIMITED, LONDON, vol. 618, no. 7966, 22 June 2023 (2023-06-22), London, pages 842 - 848, XP093238667, ISSN: 0028-0836, DOI: 10.1038/s41586-023-06133-1 *
CAMPBELL JAMES H., O’DONOGHUE PATRICK, CAMPBELL ALISHA G., SCHWIENTEK PATRICK, SCZYRBA ALEXANDER, WOYKE TANJA, SÖLL DIETER, PODAR : "UGA is an additional glycine codon in uncultured SR1 bacteria from the human microbiota", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (PNAS), NATIONAL ACADEMY OF SCIENCES, vol. 110, no. 14, 2 April 2013 (2013-04-02), pages 5540 - 5545, XP093279268, ISSN: 0027-8424, DOI: 10.1073/pnas.1303090110 *

Also Published As

Publication number Publication date
TW202521693A (zh) 2025-06-01
CN121693567A (zh) 2026-03-17

Similar Documents

Publication Publication Date Title
US20250388931A1 (en) Regulation of gene expression by aptamer-mediated modulation of alternative splicing
US11981910B2 (en) Minimal UTR sequences
US20240325427A1 (en) Treatment of amyotrophic lateral sclerosis (als)
JP7565218B2 (ja) 筋萎縮性側索硬化症および脊髄に関連する障害の治療
US20220127625A1 (en) Modulation of rep protein activity in closed-ended dna (cedna) production
KR20150005521A (ko) 세포, 기관 및 조직으로의 유전자 전이를 위한 ａａｖ 벡터 조성물 및 방법
US20240108751A1 (en) Rna-targeting compositions and methods for treating myotonic dystrophy type 1
US20240000972A1 (en) Rna-targeting compositions and methods for treating cag repeat diseases
CN117716031A (zh) 使用dkc1进行rna编辑的组合物、系统和方法
JP2024534362A (ja) 治療用タンパク質を発現させるための肝臓特異的発現カセット、ベクター、及びその使用
WO2024238321A1 (fr) Compositions et procédés de modification épigénétique ciblée
WO2025036281A1 (fr) Molécules d'arnt suppresseurs modifiées et procédés
CN119464282A (zh) 工程化抑制性tRNA分子和方法
US20250066815A1 (en) Engineered viral capsids with increased stability and methods of use thereof
WO2022170146A1 (fr) Vecteurs comprenant des séquences polynucléotidiques de remplissage
WO2026001270A1 (fr) Molécules arnt modifiées et procédés
WO2025176166A1 (fr) Cassette d'expression d'arnt modifiée
US20250170273A1 (en) Therapeutic factors for the treatment of polyq diseases
CN117545839B (zh) 工程化CRISPR-Cas13f系统及其用途
US20260002151A1 (en) Compositions and methods for the modification and regulation of liver gene expression
CN116801901A (zh) 用于治疗1型强直性肌营养不良的靶向rna的组合物和方法
HK40118673A (zh) 用於治疗polyq疾病的治疗因子

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24853690

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE